DIDEO

Classes

1-benzofurans
17alpha-estradiol 3-glucosiduronic acid
293 transfected cell
293-derived cell
3'-phospho-5'-adenylyl sulfate
4'-hydroxydiclofenac
4-hydroxytolbutamide
5'-hydroxyomeprazole
5-[2-(dimethylamino)ethyl]-2-(4-methoxyphenyl)-4-oxo-2,3,4,5-tetrahydro-1,5-benzothiazepin-3-yl acetate
6-hydroxypaclitaxel
6beta-hydroxytestosterone
7-ethoxyresorufin
7-ethoxyresorufin O-deethylation
absorbability
absorbability measurement datum
absorption of material
active ingredient
active ingredient quantification specification
adverse drug event
adverse drug reaction causality evaluation protocol
adverse event
alkaline earth coordination entity
amiodarone
anatomical system
area under curve
area under the curve ratio
assay
atorvastatin
azole
baculovirus-insect recombinant protein production host cell
benzimidazoles
benzofurans
benzothiazepine
bioavailability
bioavailability measurement datum
bioavailability ratio
biological regulation
biological role
biological_process
biomacromolecule
bodily process
breaking of covalent bond
Bufuralol
bufuralol 1'-hydroxylation
bupropion
bupropion hydroxylation
Caco-2 cell
carbon group molecular entity
carbon oxoacid
carboxylic acid
carboxylic ester
catalytic activity
causal adverse drug event
cell line
cell line cell
cell pellet
cellular metabolic process
cellular process
cellular_component
centrifugation
centrifuge pellet role
chemical entity
chemical substance
chlorzoxazone
chlorzoxazone 6-hydroxylation
CHO cell
CHO transfected cell
clearance measurement datum
clinical drug role
clinical study
clinical study design
clinically relevant potential drug-drug interaction
container
contraindication
coordination entity
coumarin
coumarin 7-hydroxylation
count
cryopreserved human hepatocyte population
cultured cell
cultured cell population
cytochrome P450
data item about biological process
data item from extrapolation
deethylation
dehydrogenation
delta-lactone
demethylation
device
dextromethorphan
dextromethorphan O-demethylation
dextrorphan
diazole
diclofenac
diclofenac 4'-hydroxylation
diclofenac 4'-hydroxylation
digestive system
dihydroxy monocarboxylic acid
Dikarya
diltiazem
dimensionless unit
dose quantification specification
dose specification
drug absorbability assay
drug administration
drug bioavailability assay
drug co-administration
drug concept set identifier
drug first pass metabolism assay
drug identifier
drug maximum concentration assay
drug maximum concentration measurement datum
drug maximum concentration ratio
drug metabolic process
drug package AUC information
drug package insert
drug product
drug product quantification specification
drug-drug interaction
drug-drug interaction description
drug-drug interaction description from drug package insert
drug-drug interaction description from FDA label information
drug-drug interaction effect
drug-drug interaction evidence
drug-drug interaction management option
E. coli recombinant protein production host cell
efflux ratio
enzyme
enzyme substrate role
Escherichia coli
establishment of localization
ester
estradiol
estradiol glucuronosylation
evaluant role
evidence data item
evidence information content entity
evidence information from a publicly reported observation-based adverse drug event report
evidence information from an evaluated observation-based case-report of a drug interaction
evidence information from an observation-based case-report of a drug interaction
evidence information from chemical analytic characterization of material
evidence information from chemical analytic metabolomics of material
evidence information from clinical study
evidence information from CYP450 drug metabolism identification experiment
evidence information from CYP450 human microsome drug metabolism identification experiment
evidence information from CYP450 human microsome drug metabolism identification experiment using antibody inhibitors
evidence information from CYP450 human microsome drug metabolism identification experiment using chemical inhibitors
evidence information from CYP450 human microsome drug metabolism inhibition experiment
evidence information from CYP450 metabolic enzyme inhibition experiment
evidence information from CYP450 recombinant drug metabolism identification experiment
evidence information from CYP450 recombinant drug metabolism identification experiment using antibody inhibitors
evidence information from CYP450 recombinant drug metabolism identification experiment using chemical inhibitors
evidence information from CYP450 recombinant drug metabolism inhibition experiment
evidence information from drug metabolism identification experiment
evidence information from drug metabolism induction experiment
evidence information from drug metabolism inhibition experiment
evidence information from drug transport protein induction experiment
evidence information from drug-drug interaction clinical trial
evidence information from genotyped pharmacokinetic trial
evidence information from non-randomized drug-drug interaction clinical trial
evidence information from OATP1B1 inhibition experiment
evidence information from OATP1B1 inhibition experiment using overexpressed cell lines
evidence information from OATP1B1 transport protein identification experiment
evidence information from OATP1B1 transport protein identification experiment using overexpressed cell lines
evidence information from OATP1B3 inhibition experiment
evidence information from OATP1B3 inhibition experiment using overexpressed cell lines
evidence information from OATP1B3 transport protein identification experiment
evidence information from OATP1B3 transport protein identification experiment using overexpressed cell lines
evidence information from observation-based adverse drug event report
evidence information from observation-based report
evidence information from observational drug-drug interaction study
evidence information from observational pharmacokinetic study
evidence information from observational study
evidence information from p-glycoprotein inhibition experiment
evidence information from p-glycoprotein inhibition experiment using Caco 2 cell lines
evidence information from p-glycoprotein inhibition experiment using overexpressed cell lines
evidence information from p-glycoprotein transport protein identification experiment
evidence information from p-glycoprotein transport protein identification experiment using Caco 2 cell lines
evidence information from p-glycoprotein transport protein identification experiment using overexpressed cell lines
evidence information from parallel groups drug-drug interaction clinical trial'
evidence information from pharmacokinetic trial
evidence information from phenotyped pharmacokinetic trial
evidence information from randomized drug-drug interaction clinical trial
evidence information from transport protein identification experiment
evidence information from transport protein inhibition experiment
evidence material information
ex vivo design
experimentally modified cell in vitro
Fa2N-4 cell
first pass effect disposition
first pass metabolism measurement datum
fluconazole
fluvastatin
fold
formation of covalent bond
freshly isolated human hepatocyte population
gastrointestinal functioning
gene expression
gene knock out
genetic transformation
genotyping
glucuronosylation
glutathione
group assignment
group randomization
half maximal effective concentration (EC50)
half maximal inhibitory concentration (IC50)
half-life ratio
HBG BC2 cell
heme-thiolate protein
hemoprotein
Hep G2 cell
Hep G2 transfected cell
HepaRG cell
hepatic clearance ratio
heteroarene
heteroatomic molecular entity
heteroorganic entity
high-speed centrifugation
Homo sapiens
human intestinal epithelial cell population
human intestine cytosolic fraction
human intestine S9 fraction
human liver cytosolic fraction
human liver S9 fraction
hydroxy carboxylic acid
hydroxy monocarboxylic acid
hydroxylation
identifier
imidazoles
immunoglobulin complex
immunoglobulin complex, circulating
import across plasma membrane
import into cell
in vitro design
individual human intestinal microsomal fraction
individual human liver microsomal fraction
information about decrease of pharmacokinetic area under the curve
information about increase of pharmacokinetic area under the curve
information biomacromolecule
inhibitor
inhibitory constant
iron protein
itraconazole
ketoconazole
lactone
lamotrigine glucuronosylation
LLC-PK subscript(1) cell
localization
lovastatin
macromolecular complex
macromolecule
magnesium coordination entity
magnesium dichloride
magnesium halide
main group molecular entity
main-group coordination entity
manufacturer role
mass value specification
material anatomical entity
material component separation
material entity participant in drug-drug interaction
material processing
MDCK cell
MDCK transfected cell
mechanism of interaction information
metabolic potential drug-drug interaction
metabolic process
metabolism induction potential drug-drug interaction
metabolism inhibition potential drug-drug interaction
metabolite
metalloprotein
microtiter plate
Midazolam
midazolam 1'-hydroxylation
mixture
molecular entity
molecular process
molecular_function
monocyclic heteroarene
multidrug resistance protein 1
NAD
NADH
NADPH
NADPH--cytochrome P450 reductase
narrow therapeutic index
negative regulation of biological process
negative regulation of metabolic process
negative regulation of transport
negative regulation of transporter activity
net flux ratio
nifedipine
nifedipine dehydrogenation
nucleic acid
nucleic acid reagent
number of doses in a day
number of liver donors
o b i 0000011
object drug information
object drug role
observation design
observational data item about drug-drug interaction
obsolete_drug-drug interaction effect
obsolete_evidence information content entity
omeprazole
omeprazole 5-hydroxylation
organic cyclic compound
organic heterobicyclic compound
organic heterocyclic compound
organic heteropolycyclic compound
organic heterotetracyclic compound
organic heterotricyclic compound
organic molecular entity
organic molecule
organism
organochalcogen compound
organooxygen compound
overexpression
p-block molecular entity
paclitaxel
paclitaxel 6-alpha hydroxylation
parallel group design
pathological bodily process
percent
percent inhibition
percentage value specification
pharmacokinetic area under curve
pharmacokinetic area under curve information
pharmacokinetic interaction signal
pharmacokinetic parameter ratio
pharmacokinetic parameter ratio decrease
pharmacokinetic parameter ratio directionality
pharmacokinetic parameter ratio increase
pharmacokinetic process
phenacetin O-deethylation
phenotype characterization
phenoxazine
physiological observation from clinical study data item
polyatomic entity
polynucleotide
pooled human intestinal microsomal fraction
pooled human liver microsomal fraction
Portion of body substance
Portion of plasma
positive regulation of biological process
potential drug-drug interaction
precipitant drug information
precipitant drug role
primary metabolic clearance enzyme role
primary total clearance enzyme role
probe subtrate role
processed material
protein
protein complex
protocol
public adverse event reporting database
racemate
ratio
ratio value specification
recombinant protein production host role
regulation of biological process
regulation of localization
regulation of transport
regulation of transporter activity
renal clearance ratio
reported drug-drug interaction
resorufin
ribonucleic acid
RNA interference oligonucleotide
RNA oligonucleotide
RNA reagent
role of scattered molecular aggregate
rosuvastatin
sandwich cultured hepatocyte population
scalar value specification
scattered molecular aggregate
severe adverse event
simvastatin
siRNA knockout Caco-2 cell
siRNA oligonucleotide
solute carrier organic anion transporter family member 1B1
solute carrier organic anion transporter family member 1B3
specimen
specimen collection process
study design
supernatant role
target of material addition role
testosterone 6-beta-hydroxylation
time to maximum drug concentration ratio
tissue specimen
tolbutamide
tolbutamide methylhydroxylation
transfection
transgenic animal hepatocyte population
transport
treatment
triazolam
triazole
triazolobenzodiazepine
U.S. Food and Drug Administration drug label
UDP-alpha-D-glucuronic acid
unit
value specification
volume of distribution ratio
Xenopus laevis

1-benzofurans^c back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/CHEBI_38830

has super-classes: benzofurans^c
has sub-classes: amiodarone^c

17alpha-estradiol 3-glucosiduronic acid^c back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/CHEBI_15822

has super-classes: organooxygen compound^c

293 transfected cell^c back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/DIDEO_00000189

Immortalized human kideny cells transfected/transduced with a transporter or enzyme; an in vitro model overexpressing transporter or enzyme of interest; used for transporter or metabolism assays

is equivalent to: 293-derived cell^c and (is_specified_output_of^op some transfection^c)
has super-classes: 293-derived cell^c

293-derived cell^c back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/CLO_0037237

has super-classes: cell line cell^c
has sub-classes: 293 transfected cell^c

3'-phospho-5'-adenylyl sulfate^c back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/CHEBI_17980

has super-classes: ester^c

4'-hydroxydiclofenac^c back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/CHEBI_59613

has super-classes: organic cyclic compound^c

4-hydroxytolbutamide^c back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/CHEBI_63799

has super-classes: organic cyclic compound^c

5'-hydroxyomeprazole^c back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/CHEBI_63840

has super-classes: benzimidazoles^c

5-[2-(dimethylamino)ethyl]-2-(4-methoxyphenyl)-4-oxo-2,3,4,5-tetrahydro-1,5-benzothiazepin-3-yl acetate^c back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/CHEBI_82814

has super-classes: benzothiazepine^c
has sub-classes: diltiazem^c

6-hydroxypaclitaxel^c back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/CHEBI_63859

has super-classes: organic molecular entity^c

6beta-hydroxytestosterone^c back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/CHEBI_34477

has super-classes: organooxygen compound^c

7-ethoxyresorufin^c back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/CHEBI_34480

has super-classes: phenoxazine^c

7-ethoxyresorufin O-deethylation^c back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/DIDEO_00000172

O-deethylation of 7-Ethoxyresorufin to form resorufin; probe substrate of CYP1A activity

is equivalent to: deethylation^c and (has input^op some 7-ethoxyresorufin^c) and (has output^op some resorufin^c)
has super-classes: deethylation^c

absorbability^c back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/DIDEO_00000034

has super-classes: b f o 0000016

absorbability measurement datum^c back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/DIDEO_00000036

is equivalent to: is_specified_output_of^op some drug absorbability assay^c
has super-classes: i a o 0000032^c; i a o 0000136^op some drug product^c

absorption of material^c back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/CHMO_0002914

Gold Book, somewhat modified. It goes on "The process of one material (absorbate) being retained by another (absorbent); this may be the physical solution of a gas, liquid, or solid in a liquid, attachment of molecules of a gas, vapour, liquid, or dissolved substance to a solid surface by physical forces, etc."

has super-classes: b f o 0000015

active ingredient^c back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/DRON_00000028

has super-classes: role of scattered molecular aggregate^c; b f o 0000054 only b f o 0000015 and (has part^op some drug administration^c) and (has part^op some b f o 0000015 and (has participant^op some scattered molecular aggregate^c) and (has participant^op some organism^c))

active ingredient quantification specification^c back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/PDRO/PDRO.owl#PDRO_0000124

has super-classes: dose quantification specification^c

adverse drug event^c back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/OAE_0000005

has super-classes: adverse event^c
has sub-classes: causal adverse drug event^c

adverse drug reaction causality evaluation protocol^c back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/DIDEO_00000087

has super-classes: protocol^c

adverse event^c back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/OAE_0000001

has super-classes: pathological bodily process^c
has sub-classes: adverse drug event^c, severe adverse event^c

alkaline earth coordination entity^c back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/CHEBI_35217

has super-classes: main-group coordination entity^c
has sub-classes: magnesium coordination entity^c

amiodarone^c back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/CHEBI_2663

has super-classes: 1-benzofurans^c

anatomical system^c back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/UBERON_0000467

has super-classes: material anatomical entity^c
has sub-classes: digestive system^c

area under curve^c back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/STATO_0000209

has super-classes: i a o 0000109^c
has sub-classes: pharmacokinetic area under curve^c

area under the curve ratio^c back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/DIDEO_00000093

has super-classes: pharmacokinetic parameter ratio^c

assay^c back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/OBI_0000070

has super-classes: o b i 0000011^c
has sub-classes: clinical study^c, drug absorbability assay^c, drug bioavailability assay^c, drug first pass metabolism assay^c, drug maximum concentration assay^c, genotyping^c, phenotype characterization^c

atorvastatin^c back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/CHEBI_39548

has super-classes: dihydroxy monocarboxylic acid^c

azole^c back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/CHEBI_68452

has super-classes: monocyclic heteroarene^c
has sub-classes: diazole^c, triazole^c

baculovirus-insect recombinant protein production host cell^c back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/DIDEO_00000168

Insect cell-hosted viral system used to produce and express recombinant proteins/enzymes; these systems are used in metabolism studies

has super-classes: cultured cell^c

benzimidazoles^c back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/CHEBI_22715

has super-classes: organic heterobicyclic compound^c
has sub-classes: 5'-hydroxyomeprazole^c

benzofurans^c back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/CHEBI_35259

has super-classes: organic heteropolycyclic compound^c
has sub-classes: 1-benzofurans^c, Bufuralol^c

benzothiazepine^c back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/CHEBI_48684

has super-classes: organic heterobicyclic compound^c
has sub-classes: 5-[2-(dimethylamino)ethyl]-2-(4-methoxyphenyl)-4-oxo-2,3,4,5-tetrahydro-1,5-benzothiazepin-3-yl acetate^c

bioavailability^c back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/DIDEO_00000010

has super-classes: b f o 0000016; inheres in^op some drug product^c

bioavailability measurement datum^c back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/DIDEO_00000025

is equivalent to: is_specified_output_of^op some drug bioavailability assay^c
has super-classes: i a o 0000032^c; i a o 0000136^op some drug product^c

bioavailability ratio^c back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/DIDEO_00000102

has super-classes: pharmacokinetic parameter ratio^c

biological regulation^c back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/GO_0065007

has super-classes: biological_process^c
has sub-classes: negative regulation of metabolic process^c, regulation of biological process^c

biological role^c back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/CHEBI_24432

has super-classes: b f o 0000023
has sub-classes: inhibitor^c

biological_process^c back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/GO_0008150

has super-classes: b f o 0000015
has sub-classes: biological regulation^c, cellular process^c, drug-drug interaction^c, drug-drug interaction effect^c, gastrointestinal functioning^c, gene expression^c, localization^c, metabolic process^c, pharmacokinetic process^c

biomacromolecule^c back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/CHEBI_33694

has super-classes: macromolecule^c
has sub-classes: information biomacromolecule^c

bodily process^c back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/OGMS_0000060

has super-classes: b f o 0000015
has sub-classes: molecular_function^c, pathological bodily process^c

breaking of covalent bond^c back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/MOP_0000780

has super-classes: molecular process^c
has sub-classes: deethylation^c, demethylation^c

Bufuralol^c back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/CHEBI_34593

has super-classes: benzofurans^c

bufuralol 1'-hydroxylation^c back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/DIDEO_00000174

1'-hydroxylation of bufuralol to form 1'-hydroxybufurolol; probe substrate of CYP2D6 activity

has super-classes: hydroxylation^c

bupropion^c back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/CHEBI_3219

has super-classes: organic cyclic compound^c

bupropion hydroxylation^c back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/DIDEO_00000176

Hydroxylation of bupropion at the 1 position to form 1-hydroxybupropion; probe substrate of CYP2B6 activity

has super-classes: hydroxylation^c

Caco-2 cell^c back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/CLO_0002172

disease: colorectal adenocarcinoma

has super-classes: cell line cell^c
has sub-classes: siRNA knockout Caco-2 cell^c

carbon group molecular entity^c back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/CHEBI_33582

has super-classes: p-block molecular entity^c
has sub-classes: organic molecular entity^c

carbon oxoacid^c back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/CHEBI_35605

has super-classes: organooxygen compound^c
has sub-classes: carboxylic acid^c

carboxylic acid^c back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/CHEBI_33575

has super-classes: carbon oxoacid^c
has sub-classes: hydroxy carboxylic acid^c

carboxylic ester^c back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/CHEBI_33308

has super-classes: ester^c
has sub-classes: lactone^c

catalytic activity^c back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/GO_0003824

has super-classes: molecular_function^c
is in domain of: realizes substrate role^op

causal adverse drug event^c back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/OAE_0000095

has super-classes: adverse drug event^c

cell line^c back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/CLO_0000031

The term 'line' is used when a culture has undergone an intentional experimental process to establish a more uniform and stable population of cells (see 'establishing cell line'). This will require one or more passages, but may involve additional selection processes. Through such passaging and/or selection processes, the resulting 'line' attains some level of genetic stability and compositional homogeneity which is typically absent in primary cultures. Because of their relative homogeneity, ‘lines’ are capable of being characterized and stably propagated over a period of time. A new *type* of cell line can be established not only through the passaging/selection of a primary culture, but also through experimental modifications of existing lines (e.g. immortalization, stable genetic modifications, drug selection for a resistant subset, etc.). The definition provided here establishes the 'scale' of cell populations that qualify as cell lines - specifically those with a shared propagation history in culture. In this way, the 'cell line' class demarcates populations that represent what researchers actually use in the practice of science - e.g. as inputs to culturing, experimentation, and sharing. The definition is such that cell lines will exhibit important attributes. For example, they will have a relatively homogenous cell type composition as they have experienced similar selective pressures due to their continuous co-propagation. In addition, these populations can also be characterized by a passage number, again owing to their common passaging history. As defined here, 'cell line' can refer to a population of cells in active culture, applied experimentally, or stored in a quiescent state for future use.

has super-classes: cultured cell population^c

cell line cell^c back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/CLO_0000001

A 'cell line cell' is a part of a cell line established through the passaging/selection of a primary cultured cells or the experimental modification of an existing cell line. New types of cell line cells are established after sufficient passaging of a primary culture to establish a stable and homogenous population that qualifies as a line (typically 1-20 passages), or following some spontaneous or experimental modification that confers novel characteristics to an existing line. A cell line cell typically has mutations of five or more genes compared to the original cell that derives the cell line cell. Some gene mutations may turn on some oncogenes. Cell line cells can be in active culture, stored in a quiescent state for future use (e.g. frozen in liquid nitrogen), or applied in experimental procedures.

has super-classes: cultured cell^c
has sub-classes: 293-derived cell^c, CHO cell^c, Caco-2 cell^c, Fa2N-4 cell^c, HBG BC2 cell^c, Hep G2 cell^c, HepaRG cell^c, LLC-PK subscript(1) cell^c, MDCK cell^c

cell pellet^c back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/OBI_1000024

has super-classes: processed material^c

cellular metabolic process^c back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/GO_0044237

has super-classes: metabolic process^c

cellular process^c back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/GO_0009987

has super-classes: biological_process^c

cellular_component^c back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/GO_0005575

Note that, in addition to forming the root of the cellular component ontology, this term is recommended for use for the annotation of gene products whose cellular component is unknown. Note that when this term is used for annotation, it indicates that no information was available about the cellular component of the gene product annotated as of the date the annotation was made; the evidence code ND, no data, is used to indicate this.

has super-classes: b f o 0000040
has sub-classes: macromolecular complex^c

centrifugation^c back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/OBI_0302886

has super-classes: material component separation^c
has sub-classes: high-speed centrifugation^c

centrifuge pellet role^c back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/OBI_0000029

has super-classes: b f o 0000023

chemical entity^c back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/CHEBI_24431

has super-classes: b f o 0000040
has sub-classes: chemical substance^c, molecular entity^c

chemical substance^c back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/CHEBI_59999

has super-classes: chemical entity^c
has sub-classes: mixture^c

chlorzoxazone^c back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/CHEBI_3655

has super-classes: organic heterobicyclic compound^c

chlorzoxazone 6-hydroxylation^c back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/DIDEO_00000197

Hydroxylation of chlorzoxazone at the 6 position to form 6-hydroxychlorzoxazone; probe substrate of CYP2E1 activity

has super-classes: hydroxylation^c

CHO cell^c back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/CLO_0002421

has super-classes: cell line cell^c
has sub-classes: CHO transfected cell^c

CHO transfected cell^c back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/DIDEO_00000186

Chinese hamster ovary cells transfected with human transporter DNA; an in vitro model used to study transporters

is equivalent to: CHO cell^c and (is_specified_output_of^op some transfection^c)
has super-classes: CHO cell^c

clearance measurement datum^c back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/DIDEO_00000089

has super-classes: i a o 0000109^c

clinical drug role^c back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/DRON_00000001

Authors:: William Hogan

has super-classes: b f o 0000023

clinical study^c back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/DIDEO_00000124

is equivalent to: assay^c and (b f o 0000055 some r o 0000059 some clinical study design^c)
has super-classes: assay^c

clinical study design^c back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/OBI_0500001

has super-classes: study design^c

clinically relevant potential drug-drug interaction^c back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/DIDEO_00000024

Alternative definitions use the risk of harm instead of the risk of an AE.

has super-classes: potential drug-drug interaction^c

container^c back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/OBI_0000967

has super-classes: device^c
has sub-classes: microtiter plate^c

contraindication^c back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/OAE_0000055

has super-classes: b f o 0000016

coordination entity^c back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/CHEBI_33240

has super-classes: heteroatomic molecular entity^c
has sub-classes: main-group coordination entity^c

coumarin^c back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/CHEBI_28794

has super-classes: organic heteropolycyclic compound^c

coumarin 7-hydroxylation^c back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/DIDEO_00000179

Hydroxylation of coumarin at the 7 position to form 7-hydroxycoumarin; probe substrate of CYP2A6 activity

has super-classes: hydroxylation^c

count^c back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/APOLLO_SV_00000032

has super-classes: i a o 0000109^c
has sub-classes: number of doses in a day^c, number of liver donors^c

cryopreserved human hepatocyte population^c back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/DIDEO_00000149

Cells isolated from human liver that have been frozen and stored, usually in liquid nitrogen; an in vitro model system for human metabolism or transport; cells can be thawed and used in metabolism or transport assays

has super-classes: cultured cell population^c

cultured cell^c back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/CL_0000010

Note that this class was re-labeled to 'cultured cell' instead of 'cell line cell', as it intent was clarified to cover any cultured cells of multicellular and unicellular organisms. This includes cells actively being cultured, or cells that have been cultured but are stored in a quiescent state for future use. In having been cultured, cells must establish homeostasis and often replicate in a foreign environment. Accomodation of this stress initiates a selection of cells fit for such challenges, wherein necessary adaptive biochemical and.or genetic changes can occur. These changes can set them apart from the in vivo cells from which they derive, and such changes will typically accumulate and change over increasing time in culture.

has super-classes: experimentally modified cell in vitro^c
has sub-classes: E. coli recombinant protein production host cell^c, baculovirus-insect recombinant protein production host cell^c, cell line cell^c

cultured cell population^c back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/OBI_0100060

The extent of a 'cultured cell population' is restricted only in that all cell members must share a propagation history (ie be derived through a common lineage of passages from an initial culture). In being defined in this way, this class can be used to refer to the populations that researchers actually use in the practice of science - ie are the inputs to culturing, experimentation, and sharing. The cells in such populations will be a relatively uniform population as they have experienced similar selective pressures due to their continuous co-propagation. And this population will also have a single passage number, again owing to their common passaging history. Cultured cell populations represent only a collection of cells (ie do not include media, culture dishes, etc), and include populations of cultured unicellular organisms or cultured multicellular organism cells. They can exist under active culture, stored in a quiescent state for future use, or applied experimentally.

has super-classes: processed material^c
has sub-classes: cell line^c, cryopreserved human hepatocyte population^c, freshly isolated human hepatocyte population^c, human intestinal epithelial cell population^c, sandwich cultured hepatocyte population^c, transgenic animal hepatocyte population^c

cytochrome P450^c back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/CHEBI_38559

has super-classes: heme-thiolate protein^c; r o 0000085 some catalytic activity^c

data item about biological process^c back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/DIDEO_00000002

is equivalent to: i a o 0000027^c and (i a o 0000136^op some biological_process^c)
has super-classes: i a o 0000027^c

data item from extrapolation^c back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/DIDEO_00000005

has super-classes: i a o 0000027^c

deethylation^c back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/MOP_0001385

has_participant: CHEBI:37807

has super-classes: breaking of covalent bond^c
has sub-classes: 7-ethoxyresorufin O-deethylation^c, phenacetin O-deethylation^c

dehydrogenation^c back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/MOP_0000590

has super-classes: b f o 0000015
has sub-classes: nifedipine dehydrogenation^c

delta-lactone^c back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/CHEBI_18946

has super-classes: lactone^c
has sub-classes: lovastatin^c, simvastatin^c

demethylation^c back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/MOP_0001364

has_participant: CHEBI:32875

has super-classes: breaking of covalent bond^c
has sub-classes: dextromethorphan O-demethylation^c

device^c back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/OBI_0000968

has super-classes: processed material^c
has sub-classes: container^c

dextromethorphan^c back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/CHEBI_4470

has super-classes: organic heterotetracyclic compound^c

dextromethorphan O-demethylation^c back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/DIDEO_00000181

O-demethylation of dextromethorphan to form dextrorphan;probe substrate of CYP2C9 activity

is equivalent to: demethylation^c and (has input^op some dextromethorphan^c) and (has output^op some dextrorphan^c)
has super-classes: demethylation^c

dextrorphan^c back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/CHEBI_29133

has super-classes: heteroorganic entity^c

diazole^c back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/CHEBI_23677

has super-classes: azole^c
has sub-classes: imidazoles^c

diclofenac^c back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/CHEBI_47381

has super-classes: organic cyclic compound^c

diclofenac 4'-hydroxylation^c back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/DIDEO_00000182

Hydroxylation of diclofenac to form 4'-hydroxydiclofenac; probe substrate of CYP2C9 activity

has super-classes: hydroxylation^c

diclofenac 4'-hydroxylation^c back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/DIDEO_00000191

Hydroxylation of diclofenac to form 4'-hydroxydiclofenac; probe substrate of CYP2C9 activity

is equivalent to: hydroxylation^c and (has input^op some diclofenac^c) and (has output^op some 4'-hydroxydiclofenac^c)
has super-classes: hydroxylation^c

digestive system^c back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/UBERON_0001007

has super-classes: anatomical system^c

dihydroxy monocarboxylic acid^c back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/CHEBI_35972

has super-classes: hydroxy monocarboxylic acid^c
has sub-classes: atorvastatin^c, rosuvastatin^c

Dikarya^c back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/NCBITaxon_451864

has super-classes: organism^c

diltiazem^c back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/CHEBI_101278

has super-classes: 5-[2-(dimethylamino)ethyl]-2-(4-methoxyphenyl)-4-oxo-2,3,4,5-tetrahydro-1,5-benzothiazepin-3-yl acetate^c

dimensionless unit^c back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/UO_0000186

has super-classes: unit^c
has sub-classes: ratio^c

dose quantification specification^c back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/PDRO/PDRO.owl#PDRO_0000123

has super-classes: i a o 0000030^c
has sub-classes: active ingredient quantification specification^c, drug product quantification specification^c

dose specification^c back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/OBI_0000969

has super-classes: i a o 0000033^c

drug absorbability assay^c back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/DIDEO_00000035

has super-classes: assay^c; o b i 0000293^op some absorbability^c and (inheres in^op some drug product^c)

drug administration^c back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/DRON_00000031

has super-classes: treatment^c; treatment^c and (has participant^op some drug product^c) and (has participant^op some organism^c)

drug bioavailability assay^c back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/DIDEO_00000026

has super-classes: assay^c; o b i 0000293^op some bioavailability^c

drug co-administration^c back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/DIDEO_00000021

An instance of this occurs when at least two or more drugs are taken in a specific time interval and the individual time interval for each drug administration overlaps with the other drug's or drugs' time interval(s). (SG1)

has super-classes: o b i 0000011^c

drug concept set identifier^c back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/DIDEO_00000128

Term and definition provided by Richard D. Boyce.

has super-classes: identifier^c

drug first pass metabolism assay^c back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/DIDEO_00000032

has super-classes: assay^c; o b i 0000293^op some first pass effect disposition^c

drug identifier^c back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/APOLLO_SV_00000461

has super-classes: identifier^c

drug maximum concentration assay^c back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/DIDEO_00000037

has super-classes: assay^c; (o b i 0000293^op some drug product^c) and (o b i 0000293^op some organism^c)

drug maximum concentration measurement datum^c back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/DIDEO_00000038

is equivalent to: is_specified_output_of^op some drug maximum concentration assay^c
has super-classes: i a o 0000032^c

drug maximum concentration ratio^c back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/DIDEO_00000099

has super-classes: pharmacokinetic parameter ratio^c

drug metabolic process^c back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/GO_0017144

has super-classes: metabolic process^c

drug package AUC information^c back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/DIDEO_00000047

is equivalent to: (part of^op some drug package insert^c) and (i a o 0000136^op some pharmacokinetic area under curve^c)
has super-classes: i a o 0000030^c

drug package insert^c back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/DIDEO_00000044

has super-classes: i a o 0000310^c
has sub-classes: U.S. Food and Drug Administration drug label^c

drug product^c back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/DRON_00000005

Authors:: William Hogan

has super-classes: b f o 0000040

drug product quantification specification^c back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/PDRO/PDRO.owl#PDRO_0000125

has super-classes: dose quantification specification^c

drug-drug interaction^c back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/DIDEO_00000020

A clinically meaningful alteration in the exposure and/or response to a drug (object drug) that has occurred as a result of the co-administration of another drug (precipitant drug)Oates JA. Chapter 5. Goodman and Gilman 11th ed (2006):117–36; Hines. Response can refer to either precipitating an adverse event or altering the therapeutic effect of the object drug. Although some DDIs may be used for therapeutic benefit, this paper focuses on those with adverse clinical consequences. (based on the 2013 DDI conference series) / has participant some mechanism.

has super-classes: biological_process^c; has occurrent part^op some drug co-administration^c; has participant^op some b f o 0000040
has sub-classes: reported drug-drug interaction^c

drug-drug interaction description^c back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/DIDEO_00000001

has super-classes: i a o 0000030^c; i a o 0000136^op some drug-drug interaction^c
has sub-classes: drug-drug interaction description from drug package insert^c

drug-drug interaction description from drug package insert^c back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/DIDEO_00000042

has super-classes: drug-drug interaction description^c
has sub-classes: drug-drug interaction description from FDA label information^c

drug-drug interaction description from FDA label information^c back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/DIDEO_00000043

has super-classes: drug-drug interaction description from drug package insert^c; part of^op some U.S. Food and Drug Administration drug label^c

drug-drug interaction effect^c back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/DIDEO_00000125

is equivalent to: process is result of^op some drug-drug interaction^c
has super-classes: biological_process^c

drug-drug interaction evidence^c back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/DIDEO_00000023

An instance of this type represents a information artifact used to establish knowledge for or against the existence of a drug-drug interaction.

has super-classes: i a o 0000030^c; i a o 0000136^op some drug co-administration^c

drug-drug interaction management option^c back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/DIDEO_00000007

An instance of this entity would represent an optional recommendation for the clinical management of patients who are exposed or about to be exposed to a potential DDI. Management options may be generated by expert opinion, consensus, and/or a review and synthesis of relevant evidence.

has super-classes: i a o 0000104^c

E. coli recombinant protein production host cell^c back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/DIDEO_00000169

Prokaryotic in vitro system used to produce and express recombinant proteins/enzymes; these systems are used in metabolism studies

is equivalent to: cultured cell^c and Escherichia coli^c and (r o 0000053^op some recombinant protein production host role^c)
has super-classes: cultured cell^c

efflux ratio^c back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/DIDEO_00000120

has super-classes: pharmacokinetic parameter ratio^c

enzyme^c back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/OBI_0000427

has super-classes: b f o 0000040
is in range of: is substrate of^op

enzyme substrate role^c back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/IDO_0100872

has super-classes: b f o 0000023
is in range of: realizes substrate role^op

Escherichia coli^c back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/NCBITaxon_562

has super-classes: organism^c

establishment of localization^c back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/GO_0051234

has super-classes: localization^c
has sub-classes: transport^c

ester^c back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/CHEBI_35701

has super-classes: organooxygen compound^c
has sub-classes: 3'-phospho-5'-adenylyl sulfate^c, carboxylic ester^c

estradiol^c back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/CHEBI_23965

has super-classes: organic cyclic compound^c

estradiol glucuronosylation^c back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/DIDEO_00000193

Glucuronidation of estradiol to estradiol-3-glucuronide; probe substrate of UGT1A1 activity (used to measure UGT1A1 activity)

has super-classes: glucuronosylation^c

evaluant role^c back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/OBI_0000067

has super-classes: b f o 0000023

evidence data item^c back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/DIDEO_00000055

is equivalent to: i a o 0000027^c and (part of^op some evidence information content entity^c) and (is_specified_output_of^op some assay^c)
has super-classes: i a o 0000027^c

evidence information content entity^c back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/DIDEO_00000053

has super-classes: i a o 0000030^c
has sub-classes: evidence information from CYP450 drug metabolism identification experiment^c, evidence information from CYP450 human microsome drug metabolism identification experiment^c, evidence information from CYP450 human microsome drug metabolism identification experiment using antibody inhibitors^c, evidence information from CYP450 human microsome drug metabolism identification experiment using chemical inhibitors^c, evidence information from CYP450 human microsome drug metabolism inhibition experiment^c, evidence information from CYP450 metabolic enzyme inhibition experiment^c, evidence information from CYP450 recombinant drug metabolism identification experiment^c, evidence information from CYP450 recombinant drug metabolism identification experiment using antibody inhibitors^c, evidence information from CYP450 recombinant drug metabolism identification experiment using chemical inhibitors^c, evidence information from CYP450 recombinant drug metabolism inhibition experiment^c, evidence information from OATP1B1 inhibition experiment^c, evidence information from OATP1B1 inhibition experiment using overexpressed cell lines^c, evidence information from OATP1B1 transport protein identification experiment^c, evidence information from OATP1B1 transport protein identification experiment using overexpressed cell lines^c, evidence information from OATP1B3 inhibition experiment^c, evidence information from OATP1B3 inhibition experiment using overexpressed cell lines^c, evidence information from OATP1B3 transport protein identification experiment^c, evidence information from OATP1B3 transport protein identification experiment using overexpressed cell lines^c, evidence information from a publicly reported observation-based adverse drug event report^c, evidence information from an evaluated observation-based case-report of a drug interaction^c, evidence information from an observation-based case-report of a drug interaction^c, evidence information from chemical analytic characterization of material^c, evidence information from chemical analytic metabolomics of material^c, evidence information from clinical study^c, evidence information from drug metabolism identification experiment^c, evidence information from drug metabolism induction experiment^c, evidence information from drug metabolism inhibition experiment^c, evidence information from drug transport protein induction experiment^c, evidence information from drug-drug interaction clinical trial^c, evidence information from genotyped pharmacokinetic trial^c, evidence information from non-randomized drug-drug interaction clinical trial^c, evidence information from observation-based adverse drug event report^c, evidence information from observation-based report^c, evidence information from observational drug-drug interaction study^c, evidence information from observational pharmacokinetic study^c, evidence information from observational study^c, evidence information from p-glycoprotein inhibition experiment^c, evidence information from p-glycoprotein inhibition experiment using Caco 2 cell lines^c, evidence information from p-glycoprotein inhibition experiment using overexpressed cell lines^c, evidence information from p-glycoprotein transport protein identification experiment^c, evidence information from p-glycoprotein transport protein identification experiment using Caco 2 cell lines^c, evidence information from p-glycoprotein transport protein identification experiment using overexpressed cell lines^c, evidence information from parallel groups drug-drug interaction clinical trial'^c, evidence information from pharmacokinetic trial^c, evidence information from phenotyped pharmacokinetic trial^c, evidence information from randomized drug-drug interaction clinical trial^c, evidence information from transport protein identification experiment^c, evidence information from transport protein inhibition experiment^c

evidence information from a publicly reported observation-based adverse drug event report^c back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/DIDEO_00000083

is equivalent to: evidence information content entity^c and (part of^op some public adverse event reporting database^c) and (i a o 0000136^op some assay^c and (causally downstream of^op some adverse drug event^c and (preceded by^op some drug administration^c and (has participant^op some chemical entity^c or drug product^c))))
has super-classes: evidence information content entity^c

evidence information from an evaluated observation-based case-report of a drug interaction^c back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/DIDEO_00000088

is equivalent to: evidence information content entity^c and (i a o 0000136^op some assay^c and (causally downstream of^op some adverse drug event^c and (preceded by^op some drug administration^c and (has participant^op some (chemical entity^c or drug product^c) and (r o 0000053^op some object drug role^c)) and (has participant^op some (chemical entity^c or drug product^c) and (r o 0000053^op some precipitant drug role^c))))) and (is_specified_output_of^op some o b i 0000011^c and (b f o 0000055 some r o 0000059 some adverse drug reaction causality evaluation protocol^c))
has super-classes: evidence information content entity^c

evidence information from an observation-based case-report of a drug interaction^c back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/DIDEO_00000084

is equivalent to: evidence information content entity^c and (i a o 0000136^op some assay^c and (causally downstream of^op some adverse drug event^c and (preceded by^op some drug administration^c and (has participant^op some (chemical entity^c or drug product^c) and (r o 0000053^op some object drug role^c)) and (has participant^op some (chemical entity^c or drug product^c) and (r o 0000053^op some precipitant drug role^c)))))
has super-classes: evidence information content entity^c

evidence information from chemical analytic characterization of material^c back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/DIDEO_00005004

has super-classes: evidence information content entity^c

evidence information from chemical analytic metabolomics of material^c back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/DIDEO_00005005

has super-classes: evidence information content entity^c

evidence information from clinical study^c back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/DIDEO_00000056

is equivalent to: evidence information content entity^c and (i a o 0000136^op some assay^c and (b f o 0000055 some r o 0000059 some clinical study design^c) and (o b i 0000293^op some chemical entity^c or drug product^c))
has super-classes: evidence information content entity^c

evidence information from CYP450 drug metabolism identification experiment^c back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/DIDEO_00000063

is equivalent to: evidence information content entity^c and (i a o 0000136^op some assay^c and (b f o 0000055 some r o 0000059 some in vitro design^c) and (o b i 0000293^op some chemical substance^c and ((part of^op some drug product^c) or (r o 0000053^op some metabolite^c)) and (participates in^op some metabolic process^c and (has participant^op some cytochrome P450^c))) and (o b i 0000293^op some cell line^c or tissue specimen^c))
has super-classes: evidence information content entity^c

evidence information from CYP450 human microsome drug metabolism identification experiment^c back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/DIDEO_00000067

is equivalent to: evidence information content entity^c and (i a o 0000136^op some assay^c and (b f o 0000055 some r o 0000059 some in vitro design^c) and (o b i 0000293^op some chemical substance^c and ((part of^op some drug product^c) or (r o 0000053^op some metabolite^c)) and (participates in^op some metabolic process^c and (has participant^op some cytochrome P450^c))) and (o b i 0000293^op some tissue specimen^c and (is_specified_output_of^op some specimen collection process^c and (o b i 0000293^op some Homo sapiens^c))))
has super-classes: evidence information content entity^c

evidence information from CYP450 human microsome drug metabolism identification experiment using antibody inhibitors^c back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/DIDEO_00000069

is equivalent to: evidence information content entity^c and (i a o 0000136^op some assay^c and (b f o 0000055 some r o 0000059 some in vitro design^c) and (o b i 0000293^op some chemical substance^c and ((part of^op some drug product^c) or (r o 0000053^op some metabolite^c)) and (participates in^op some metabolic process^c and (has participant^op some cytochrome P450^c))) and (o b i 0000293^op some immunoglobulin complex, circulating^c and (r o 0000053^op some inhibitor^c)) and (o b i 0000293^op some tissue specimen^c and (is_specified_output_of^op some specimen collection process^c and (o b i 0000293^op some Homo sapiens^c))))
has super-classes: evidence information content entity^c

evidence information from CYP450 human microsome drug metabolism identification experiment using chemical inhibitors^c back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/DIDEO_00000068

is equivalent to: evidence information content entity^c and (i a o 0000136^op some assay^c and (b f o 0000055 some r o 0000059 some in vitro design^c) and (o b i 0000293^op some chemical substance^c and ((part of^op some drug product^c) or (r o 0000053^op some metabolite^c)) and (participates in^op some metabolic process^c and (has participant^op some cytochrome P450^c))) and (o b i 0000293^op some chemical substance^c and (not (immunoglobulin complex, circulating^c)) and (r o 0000053^op some inhibitor^c)) and (o b i 0000293^op some tissue specimen^c and (is_specified_output_of^op some specimen collection process^c and (o b i 0000293^op some Homo sapiens^c))))
has super-classes: evidence information content entity^c

evidence information from CYP450 human microsome drug metabolism inhibition experiment^c back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/DIDEO_00000081

is equivalent to: evidence information content entity^c and (i a o 0000136^op some assay^c and (b f o 0000055 some r o 0000059 some in vitro design^c) and (o b i 0000293^op some chemical substance^c and ((part of^op some drug product^c) or (r o 0000053^op some metabolite^c)) and (participates in^op some negative regulation of metabolic process^c and (has participant^op some cytochrome P450^c))) and (o b i 0000293^op some tissue specimen^c and (is_specified_output_of^op some specimen collection process^c and (o b i 0000293^op some Homo sapiens^c))))
has super-classes: evidence information content entity^c

evidence information from CYP450 metabolic enzyme inhibition experiment^c back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/DIDEO_00000070

is equivalent to: evidence information content entity^c and (i a o 0000136^op some assay^c and (b f o 0000055 some r o 0000059 some in vitro design^c) and (o b i 0000293^op some chemical substance^c and ((part of^op some drug product^c) or (r o 0000053^op some metabolite^c)) and (participates in^op some negative regulation of metabolic process^c and (has participant^op some cytochrome P450^c))) and (o b i 0000293^op some cell line^c or tissue specimen^c))
has super-classes: evidence information content entity^c

evidence information from CYP450 recombinant drug metabolism identification experiment^c back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/DIDEO_00000064

is equivalent to: evidence information content entity^c and (i a o 0000136^op some assay^c and (b f o 0000055 some r o 0000059 some in vitro design^c) and (o b i 0000293^op some cell line^c) and (o b i 0000293^op some chemical substance^c and ((part of^op some drug product^c) or (r o 0000053^op some metabolite^c)) and (participates in^op some metabolic process^c and (has participant^op some cytochrome P450^c))))
has super-classes: evidence information content entity^c

evidence information from CYP450 recombinant drug metabolism identification experiment using antibody inhibitors^c back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/DIDEO_00000066

is equivalent to: evidence information content entity^c and (i a o 0000136^op some assay^c and (b f o 0000055 some r o 0000059 some in vitro design^c) and (o b i 0000293^op some cell line^c) and (o b i 0000293^op some chemical substance^c and ((part of^op some drug product^c) or (r o 0000053^op some metabolite^c)) and (participates in^op some metabolic process^c and (has participant^op some cytochrome P450^c))) and (o b i 0000293^op some immunoglobulin complex, circulating^c and (r o 0000053^op some inhibitor^c)))
has super-classes: evidence information content entity^c

evidence information from CYP450 recombinant drug metabolism identification experiment using chemical inhibitors^c back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/DIDEO_00000065

is equivalent to: evidence information content entity^c and (i a o 0000136^op some assay^c and (b f o 0000055 some r o 0000059 some in vitro design^c) and (o b i 0000293^op some cell line^c) and (o b i 0000293^op some chemical substance^c and ((part of^op some drug product^c) or (r o 0000053^op some metabolite^c)) and (participates in^op some metabolic process^c and (has participant^op some cytochrome P450^c))) and (o b i 0000293^op some chemical substance^c and (not (immunoglobulin complex, circulating^c)) and (r o 0000053^op some inhibitor^c)))
has super-classes: evidence information content entity^c

evidence information from CYP450 recombinant drug metabolism inhibition experiment^c back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/DIDEO_00000080

is equivalent to: evidence information content entity^c and (i a o 0000136^op some assay^c and (b f o 0000055 some r o 0000059 some in vitro design^c) and (o b i 0000293^op some cell line^c) and (o b i 0000293^op some chemical substance^c and ((part of^op some drug product^c) or (r o 0000053^op some metabolite^c)) and (participates in^op some negative regulation of metabolic process^c and (has participant^op some cytochrome P450^c))))
has super-classes: evidence information content entity^c

evidence information from drug metabolism identification experiment^c back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/DIDEO_00000057

is equivalent to: evidence information content entity^c and (i a o 0000136^op some assay^c and (b f o 0000055 some r o 0000059 some in vitro design^c) and (o b i 0000293^op some chemical substance^c and ((part of^op some drug product^c) or (r o 0000053^op some metabolite^c)) and (participates in^op some metabolic process^c and (has participant^op some (ribonucleic acid^c or protein^c) or (has part^op some ribonucleic acid^c or (protein^c and (r o 0000085 some catalytic activity^c)))))) and (o b i 0000293^op some cell line^c or tissue specimen^c))
has super-classes: evidence information content entity^c

evidence information from drug metabolism induction experiment^c back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/DIDEO_00005000

has super-classes: evidence information content entity^c

evidence information from drug metabolism inhibition experiment^c back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/DIDEO_00000058

is equivalent to: evidence information content entity^c and (i a o 0000136^op some assay^c and (b f o 0000055 some r o 0000059 some in vitro design^c) and (o b i 0000293^op some chemical substance^c and ((part of^op some drug product^c) or (r o 0000053^op some metabolite^c)) and (participates in^op some negative regulation of metabolic process^c and (has participant^op some ((ribonucleic acid^c or protein^c) or (has part^op some ribonucleic acid^c or protein^c)) and (r o 0000085 some catalytic activity^c)))) and (o b i 0000293^op some cell line^c or tissue specimen^c))
has super-classes: evidence information content entity^c

evidence information from drug transport protein induction experiment^c back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/DIDEO_00005002

has super-classes: evidence information content entity^c

evidence information from drug-drug interaction clinical trial^c back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/DIDEO_00000071

is equivalent to: evidence information content entity^c and (i a o 0000136^op some assay^c and (b f o 0000055 some r o 0000059 some clinical study design^c) and (o b i 0000293^op some (chemical entity^c or drug product^c) and (r o 0000053^op some object drug role^c)) and (o b i 0000293^op some (chemical entity^c or drug product^c) and (r o 0000053^op some precipitant drug role^c)))
has super-classes: evidence information content entity^c

evidence information from genotyped pharmacokinetic trial^c back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/DIDEO_00000076

is equivalent to: evidence information content entity^c and (i a o 0000136^op some assay^c and (b f o 0000055 some r o 0000059 some clinical study design^c) and (o b i 0000293^op some organism^c and (participates in^op some pharmacokinetic process^c) and (participates in^op some genotyping^c)) and (o b i 0000293^op some chemical entity^c or drug product^c))
has super-classes: evidence information content entity^c

evidence information from non-randomized drug-drug interaction clinical trial^c back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/DIDEO_00000072

is equivalent to: evidence information content entity^c and (i a o 0000136^op some assay^c and (not (has part^op value group randomization)) and (b f o 0000055 some r o 0000059 some clinical study design^c) and (o b i 0000293^op some (chemical entity^c or drug product^c) and (r o 0000053^op some object drug role^c)) and (o b i 0000293^op some (chemical entity^c or drug product^c) and (r o 0000053^op some precipitant drug role^c)))
has super-classes: evidence information content entity^c

evidence information from OATP1B1 inhibition experiment^c back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/DIDEO_00000114

is equivalent to: evidence information content entity^c and (i a o 0000136^op some assay^c and (b f o 0000055 some r o 0000059 some ex vivo design^c) and (o b i 0000293^op some chemical substance^c and (is_specified_output_of^op some negative regulation of transporter activity^c and (has participant^op some solute carrier organic anion transporter family member 1B1^c) and (has participant^op some chemical substance^c and (part of^op some drug product^c)))))
has super-classes: evidence information content entity^c

evidence information from OATP1B1 inhibition experiment using overexpressed cell lines^c back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/DIDEO_00000115

is equivalent to: evidence information content entity^c and (i a o 0000136^op some assay^c and (b f o 0000055 some r o 0000059 some ex vivo design^c) and (o b i 0000293^op some chemical substance^c and (is_specified_output_of^op some negative regulation of transporter activity^c and (has participant^op some solute carrier organic anion transporter family member 1B1^c) and (has participant^op some chemical substance^c and (part of^op some drug product^c)))) and (o b i 0000293^op some cell line cell^c and (participates in^op some overexpression^c)))
has super-classes: evidence information content entity^c

evidence information from OATP1B1 transport protein identification experiment^c back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/DIDEO_00000107

is equivalent to: evidence information content entity^c and (i a o 0000136^op some assay^c and (b f o 0000055 some r o 0000059 some ex vivo design^c) and (o b i 0000293^op some chemical substance^c and (is_specified_output_of^op some import across plasma membrane^c and (has participant^op some solute carrier organic anion transporter family member 1B1^c) and (has participant^op some chemical substance^c and (part of^op some drug product^c)))))
has super-classes: evidence information content entity^c

evidence information from OATP1B1 transport protein identification experiment using overexpressed cell lines^c back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/DIDEO_00000109

is equivalent to: evidence information content entity^c and (i a o 0000136^op some assay^c and (b f o 0000055 some r o 0000059 some ex vivo design^c) and (o b i 0000293^op some chemical substance^c and (is_specified_output_of^op some import across plasma membrane^c and (has participant^op some solute carrier organic anion transporter family member 1B1^c) and (has participant^op some chemical substance^c and (part of^op some drug product^c)))) and (o b i 0000293^op some cell line cell^c and (participates in^op some overexpression^c)))
has super-classes: evidence information content entity^c

evidence information from OATP1B3 inhibition experiment^c back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/DIDEO_00000117

is equivalent to: evidence information content entity^c and (i a o 0000136^op some assay^c and (b f o 0000055 some r o 0000059 some ex vivo design^c) and (o b i 0000293^op some chemical substance^c and (is_specified_output_of^op some negative regulation of transporter activity^c and (has participant^op some solute carrier organic anion transporter family member 1B3^c) and (has participant^op some chemical substance^c and (part of^op some drug product^c)))))
has super-classes: evidence information content entity^c

evidence information from OATP1B3 inhibition experiment using overexpressed cell lines^c back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/DIDEO_00000116

is equivalent to: evidence information content entity^c and (i a o 0000136^op some assay^c and (b f o 0000055 some r o 0000059 some ex vivo design^c) and (o b i 0000293^op some chemical substance^c and (is_specified_output_of^op some negative regulation of transporter activity^c and (has participant^op some solute carrier organic anion transporter family member 1B3^c) and (has participant^op some chemical substance^c and (part of^op some drug product^c)))) and (o b i 0000293^op some cell line cell^c and (participates in^op some overexpression^c)))
has super-classes: evidence information content entity^c

evidence information from OATP1B3 transport protein identification experiment^c back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/DIDEO_00000108

is equivalent to: evidence information content entity^c and (i a o 0000136^op some assay^c and (b f o 0000055 some r o 0000059 some ex vivo design^c) and (o b i 0000293^op some chemical substance^c and (is_specified_output_of^op some import across plasma membrane^c and (has participant^op some solute carrier organic anion transporter family member 1B3^c) and (has participant^op some chemical substance^c and (part of^op some drug product^c)))))
has super-classes: evidence information content entity^c

evidence information from OATP1B3 transport protein identification experiment using overexpressed cell lines^c back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/DIDEO_00000110

is equivalent to: evidence information content entity^c and (i a o 0000136^op some assay^c and (b f o 0000055 some r o 0000059 some ex vivo design^c) and (o b i 0000293^op some chemical substance^c and (is_specified_output_of^op some import across plasma membrane^c and (has participant^op some solute carrier organic anion transporter family member 1B3^c) and (has participant^op some chemical substance^c and (part of^op some drug product^c)))) and (o b i 0000293^op some cell line cell^c and (participates in^op some overexpression^c)))
has super-classes: evidence information content entity^c

evidence information from observation-based adverse drug event report^c back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/DIDEO_00000061

is equivalent to: evidence information content entity^c and (i a o 0000136^op some assay^c and (causally downstream of^op some adverse drug event^c and (preceded by^op some drug administration^c and (has participant^op some chemical entity^c or drug product^c))))
has super-classes: evidence information content entity^c

evidence information from observation-based report^c back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/DIDEO_00000077

is equivalent to: evidence information content entity^c and (i a o 0000136^op some assay^c and (causally downstream of^op some b f o 0000003))
has super-classes: evidence information content entity^c

evidence information from observational drug-drug interaction study^c back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/DIDEO_00000079

is equivalent to: evidence information content entity^c and (i a o 0000136^op some (assay^c and (b f o 0000055 some r o 0000059 some observation design^c)) and (o b i 0000293^op some drug product^c and (r o 0000053^op some object drug role^c)) and (o b i 0000293^op some drug product^c and (r o 0000053^op some precipitant drug role^c)) and (o b i 0000293^op some organism^c and (participates in^op some pharmacokinetic process^c)))
has super-classes: evidence information content entity^c

evidence information from observational pharmacokinetic study^c back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/DIDEO_00000078

is equivalent to: evidence information content entity^c and (i a o 0000136^op some (assay^c and (b f o 0000055 some r o 0000059 some observation design^c)) and (o b i 0000293^op some drug product^c) and (o b i 0000293^op some organism^c and (participates in^op some pharmacokinetic process^c)))
has super-classes: evidence information content entity^c

evidence information from observational study^c back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/DIDEO_00000062

is equivalent to: evidence information content entity^c and (i a o 0000136^op some (assay^c and (b f o 0000055 some r o 0000059 some observation design^c)) and (o b i 0000293^op some b f o 0000040))
has super-classes: evidence information content entity^c

evidence information from p-glycoprotein inhibition experiment^c back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/DIDEO_00000111

is equivalent to: evidence information content entity^c and (i a o 0000136^op some assay^c and (b f o 0000055 some r o 0000059 some ex vivo design^c) and (o b i 0000293^op some chemical substance^c and (is_specified_output_of^op some negative regulation of transporter activity^c and (has participant^op some multidrug resistance protein 1^c) and (has participant^op some chemical substance^c and (part of^op some drug product^c)))))
has super-classes: evidence information content entity^c

evidence information from p-glycoprotein inhibition experiment using Caco 2 cell lines^c back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/DIDEO_00000112

is equivalent to: evidence information content entity^c and (i a o 0000136^op some assay^c and (b f o 0000055 some r o 0000059 some ex vivo design^c) and (o b i 0000293^op some Caco-2 cell^c) and (o b i 0000293^op some chemical substance^c and (is_specified_output_of^op some negative regulation of transporter activity^c and (has participant^op some multidrug resistance protein 1^c) and (has participant^op some chemical substance^c and (part of^op some drug product^c)))))
has super-classes: evidence information content entity^c

evidence information from p-glycoprotein inhibition experiment using overexpressed cell lines^c back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/DIDEO_00000113

is equivalent to: evidence information content entity^c and (i a o 0000136^op some assay^c and (b f o 0000055 some r o 0000059 some ex vivo design^c) and (o b i 0000293^op some chemical substance^c and (is_specified_output_of^op some negative regulation of transporter activity^c and (has participant^op some multidrug resistance protein 1^c) and (has participant^op some chemical substance^c and (part of^op some drug product^c)))) and (o b i 0000293^op some cell line cell^c and (participates in^op some overexpression^c)))
has super-classes: evidence information content entity^c

evidence information from p-glycoprotein transport protein identification experiment^c back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/DIDEO_00000104

is equivalent to: evidence information content entity^c and (i a o 0000136^op some assay^c and (b f o 0000055 some r o 0000059 some ex vivo design^c) and (o b i 0000293^op some chemical substance^c and (is_specified_output_of^op some import across plasma membrane^c and (has participant^op some multidrug resistance protein 1^c) and (has participant^op some chemical substance^c and (part of^op some drug product^c)))))
has super-classes: evidence information content entity^c

evidence information from p-glycoprotein transport protein identification experiment using Caco 2 cell lines^c back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/DIDEO_00000105

is equivalent to: evidence information content entity^c and (i a o 0000136^op some assay^c and (b f o 0000055 some r o 0000059 some ex vivo design^c) and (o b i 0000293^op some Caco-2 cell^c) and (o b i 0000293^op some chemical substance^c and (is_specified_output_of^op some import across plasma membrane^c and (has participant^op some multidrug resistance protein 1^c) and (has participant^op some chemical substance^c and (part of^op some drug product^c)))))
has super-classes: evidence information content entity^c

evidence information from p-glycoprotein transport protein identification experiment using overexpressed cell lines^c back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/DIDEO_00000106

is equivalent to: evidence information content entity^c and (i a o 0000136^op some assay^c and (b f o 0000055 some r o 0000059 some ex vivo design^c) and (o b i 0000293^op some chemical substance^c and (is_specified_output_of^op some import across plasma membrane^c and (has participant^op some multidrug resistance protein 1^c) and (has participant^op some chemical substance^c and (part of^op some drug product^c)))) and (o b i 0000293^op some cell line cell^c and (participates in^op some overexpression^c)))
has super-classes: evidence information content entity^c

evidence information from parallel groups drug-drug interaction clinical trial'^c back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/DIDEO_00000073

is equivalent to: evidence information content entity^c and (i a o 0000136^op some assay^c and (not (has part^op value group randomization)) and (b f o 0000055 some r o 0000059 some clinical study design^c and (has part^op some parallel group design^c)) and (o b i 0000293^op some (chemical entity^c or drug product^c) and (r o 0000053^op some object drug role^c)) and (o b i 0000293^op some (chemical entity^c or drug product^c) and (r o 0000053^op some precipitant drug role^c)))
has super-classes: evidence information content entity^c

evidence information from pharmacokinetic trial^c back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/DIDEO_00000075

is equivalent to: evidence information content entity^c and (i a o 0000136^op some assay^c and (b f o 0000055 some r o 0000059 some clinical study design^c) and (o b i 0000293^op some organism^c and (participates in^op some pharmacokinetic process^c)) and (o b i 0000293^op some chemical entity^c or drug product^c))
has super-classes: evidence information content entity^c

evidence information from phenotyped pharmacokinetic trial^c back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/DIDEO_00000103

is equivalent to: evidence information content entity^c and (i a o 0000136^op some assay^c and (b f o 0000055 some r o 0000059 some clinical study design^c) and (o b i 0000293^op some organism^c and (participates in^op some pharmacokinetic process^c) and (participates in^op some phenotype characterization^c)) and (o b i 0000293^op some chemical entity^c or drug product^c))
has super-classes: evidence information content entity^c

evidence information from randomized drug-drug interaction clinical trial^c back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/DIDEO_00000074

is equivalent to: evidence information content entity^c and (i a o 0000136^op some assay^c and (has part^op some group randomization^c) and (b f o 0000055 some r o 0000059 some clinical study design^c) and (o b i 0000293^op some (chemical entity^c or drug product^c) and (r o 0000053^op some object drug role^c)) and (o b i 0000293^op some (chemical entity^c or drug product^c) and (r o 0000053^op some precipitant drug role^c)))
has super-classes: evidence information content entity^c

evidence information from transport protein identification experiment^c back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/DIDEO_00000059

is equivalent to: evidence information content entity^c and (i a o 0000136^op some assay^c and (b f o 0000055 some r o 0000059 some ex vivo design^c) and (o b i 0000293^op some chemical substance^c and (is_specified_output_of^op some import across plasma membrane^c and (has participant^op some protein^c) and (has participant^op some chemical substance^c and (part of^op some drug product^c)))))
has super-classes: evidence information content entity^c

evidence information from transport protein inhibition experiment^c back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/DIDEO_00000060

is equivalent to: evidence information content entity^c and (i a o 0000136^op some assay^c and (b f o 0000055 some r o 0000059 some ex vivo design^c) and (o b i 0000293^op some chemical substance^c and (is_specified_output_of^op some negative regulation of transporter activity^c and (has participant^op some protein^c) and (has participant^op some chemical substance^c and (part of^op some drug product^c)))))
has super-classes: evidence information content entity^c

evidence material information^c back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/DIDEO_00000054

is equivalent to: i a o 0000030^c and (part of^op some evidence information content entity^c) and (i a o 0000142^op some b f o 0000001^c and (is_specified_input_of^op some assay^c))
has super-classes: i a o 0000030^c

ex vivo design^c back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/OBI_0001211

has super-classes: study design^c

experimentally modified cell in vitro^c back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/CL_0000578

This class has been re-labeled to imply reference only to in vitro experimentally modified cells, similarly, the definition has been slightly updated to reflect this. 'experimentally modified cell' refers only to cells in vitro, and not modified in vivo/in environment cells. There is currently no class representing unmodified in vitro cells (other than the parent 'cell in vitro'), or a class representing modified native cells. More granular subclassing of experimentally modified cell can be found in ReO. MHB 1.12.12

has super-classes: processed material^c
has sub-classes: cultured cell^c

Fa2N-4 cell^c back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/DIDEO_00000158

Fa2N-4 cell line was prepared by immortalizing hepatocytes from a 12 year-old Caucasian female donor with Simian virus 40 large T antigen. The donor was tested negative for CMV, HIV, HBV, and HCV. This cell line was mainly used for major CYP induction studies (including CYP3A4/5, 1A2, 2B6, and 2C9) with limitations. Hepatic transporter expression levels are low.

has super-classes: cell line cell^c

first pass effect disposition^c back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/DIDEO_00000031

has super-classes: b f o 0000016; inheres in^op some drug product^c

first pass metabolism measurement datum^c back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/DIDEO_00000033

is equivalent to: is_specified_output_of^op some drug first pass metabolism assay^c
has super-classes: i a o 0000032^c; i a o 0000136^op some drug product^c

fluconazole^c back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/CHEBI_46081

has super-classes: triazole^c

fluvastatin^c back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/CHEBI_38561

has super-classes: racemate^c

fold^c back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/DIDEO_00000091

has super-classes: ratio^c

formation of covalent bond^c back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/MOP_0000779

has super-classes: molecular process^c
has sub-classes: glucuronosylation^c, hydroxylation^c

freshly isolated human hepatocyte population^c back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/DIDEO_00000152

Cells isolated from human liver, never frozen; an in vitro model system for human metabolism or transport; cells can be used in metabolism or transport assays

has super-classes: cultured cell population^c

gastrointestinal functioning^c back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/DIDEO_00000006

Physiological activity and functions of the gastrointestinal system as a whole or of any of its parts, including digestion, absorption and eliminating waste.

is equivalent to: b f o 0000055 some b f o 0000034 and (inheres in^op some part of^op some digestive system^c)
has super-classes: biological_process^c

gene expression^c back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/INO_0000102

has super-classes: biological_process^c
has sub-classes: overexpression^c

gene knock out^c back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/OBI_0001148

has super-classes: genetic transformation^c

genetic transformation^c back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/OBI_0600043

has super-classes: material processing^c
has sub-classes: gene knock out^c, transfection^c

genotyping^c back to ToC or Class ToC

IRI: http://www.ebi.ac.uk/efo/EFO_0000750

has super-classes: assay^c

glucuronosylation^c back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/MOP_0000156

has_participant: CHEBI:24303

has super-classes: formation of covalent bond^c
has sub-classes: estradiol glucuronosylation^c, lamotrigine glucuronosylation^c

glutathione^c back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/CHEBI_16856

has super-classes: organooxygen compound^c

group assignment^c back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/OBI_0600015

has super-classes: o b i 0000011^c
has sub-classes: group randomization^c

group randomization^c back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/OBI_0302900

has super-classes: group assignment^c
has members: group randomizationⁿⁱ
is also defined as: named individual

half maximal effective concentration (EC50)^c back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/OBI_0001180

has super-classes: i a o 0000032^c

half maximal inhibitory concentration (IC50)^c back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/OBI_0001191

has super-classes: i a o 0000032^c

half-life ratio^c back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/DIDEO_00000100

has super-classes: pharmacokinetic parameter ratio^c

HBG BC2 cell^c back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/DIDEO_00000159

An Immortalized human hepatoma cell line possesses the capacities of being reversibly differentiated in vitro, and of maintaining a relatviely higher mtabolic rate in the differentiated phase. It is mainly used for repeated toxicity evaluation in vitro.

has super-classes: cell line cell^c

heme-thiolate protein^c back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/CHEBI_36074

has super-classes: hemoprotein^c
has sub-classes: cytochrome P450^c

hemoprotein^c back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/CHEBI_35137

has super-classes: iron protein^c
has sub-classes: heme-thiolate protein^c

Hep G2 cell^c back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/DIDEO_00000185

HepG2 was derived from a liver hepatocellular carcinoma of a 15 year-old Caucasian male. HepG2 cells secrete a variety of major plasma proteins. They are a suitable in vitro model system for the study of polarized human hepatocytes, with high degree of morphological and functional differentiation in vitro. It can be used for hepatic metabolism, transport, and toxicity evaluations in vitro. It was tested negative for HBV.

has super-classes: cell line cell^c
has sub-classes: Hep G2 transfected cell^c

Hep G2 transfected cell^c back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/DIDEO_00000187

Well characterized immortalized human liver cancer cell line used as an in vitro model system of metabolism or transport

is equivalent to: Hep G2 cell^c and (is_specified_output_of^op some transfection^c)
has super-classes: Hep G2 cell^c

HepaRG cell^c back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/DIDEO_00000157

HepaRG cells are terminally differentiated human hepatocellular carcinoma cells that reproducibly express drug-metabolizing enzymes and transporters. They are commonly used for metabolism and transport evaluations in vitro, as they respond and function like primary human hepatocytes across a range of applications.

has super-classes: cell line cell^c

hepatic clearance ratio^c back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/DIDEO_00000101

has super-classes: pharmacokinetic parameter ratio^c

heteroarene^c back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/CHEBI_33833

has super-classes: organic heterocyclic compound^c
has sub-classes: NAD^c, NADPH^c, UDP-alpha-D-glucuronic acid^c, monocyclic heteroarene^c

heteroatomic molecular entity^c back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/CHEBI_37577

has super-classes: polyatomic entity^c
has sub-classes: coordination entity^c

heteroorganic entity^c back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/CHEBI_33285

has super-classes: organic molecular entity^c
has sub-classes: dextrorphan^c, organochalcogen compound^c

high-speed centrifugation^c back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/CHMO_0002013

has super-classes: centrifugation^c

Homo sapiens^c back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/NCBITaxon_9606

has super-classes: organism^c

human intestinal epithelial cell population^c back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/DIDEO_00000155

has super-classes: cultured cell population^c

human intestine cytosolic fraction^c back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/DIDEO_00000161

Cell cytosol obtained via centrifugation of human enterocytes. It is commonly used to support in vitro evaluation of intestinal cytosolic enzymes in the first-pass metabolism of orally ingested xenobitotics.

has super-classes: processed material^c

human intestine S9 fraction^c back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/DIDEO_00000167

A mixture of cell cytosol and microsomes isolated by disruption and centrifugation of human enterocytes. It contains a wide range of drug-metabolizing enzymes and is commonly used for in vitro DMPK studies, including both phase I and phase II xenobiotic metabolism.

has super-classes: processed material^c

human liver cytosolic fraction^c back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/DIDEO_00000160

Cell cytosol obtained via centrifugation of human liver cells. It is commonly used to support in vitro DMPK studies related to liver cytsolic enzymes, especially non-CYP enzymes, such as phase I enzyme aldehyde oxidase (AO), phase II enzyme SULT.

has super-classes: processed material^c

human liver S9 fraction^c back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/DIDEO_00000162

A mixture of cell cytosol and microsomes isolated by disruption and centrifugation of human liver cells. It contains a wide range of drug-metabolizing enzymes and is commonly used for in vitro DMPK studies, including both phase I and phase II xenobiotic metabolism.

has super-classes: processed material^c

hydroxy carboxylic acid^c back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/CHEBI_24669

has super-classes: carboxylic acid^c
has sub-classes: hydroxy monocarboxylic acid^c

hydroxy monocarboxylic acid^c back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/CHEBI_35868

has super-classes: hydroxy carboxylic acid^c
has sub-classes: dihydroxy monocarboxylic acid^c

hydroxylation^c back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/MOP_0000673

has super-classes: formation of covalent bond^c
has sub-classes: bufuralol 1'-hydroxylation^c, bupropion hydroxylation^c, chlorzoxazone 6-hydroxylation^c, coumarin 7-hydroxylation^c, diclofenac 4'-hydroxylation^c, diclofenac 4'-hydroxylation^c, midazolam 1'-hydroxylation^c, omeprazole 5-hydroxylation^c, paclitaxel 6-alpha hydroxylation^c, testosterone 6-beta-hydroxylation^c, tolbutamide methylhydroxylation^c

identifier^c back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/IAO_0020000

Authors:: Mathias Brochhausen

Sep 29, 2016: The current definition has been amended from the previous version: "A proper name is an information content entity that is the outcome of a dubbing process and is used to refer to one instance of entity shared by a group of people to refer to that individual entity." to more accuratly reflect the necessary and sufficient condition on the class. (MB)

has super-classes: i a o 0000030^c
has sub-classes: drug concept set identifier^c, drug identifier^c

imidazoles^c back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/CHEBI_24780

has super-classes: diazole^c
has sub-classes: ketoconazole^c

immunoglobulin complex^c back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/GO_0019814

Note that an immunoglobulin complex has the function of antigen binding if a suitable antigen is available.

has super-classes: protein complex^c
has sub-classes: immunoglobulin complex, circulating^c

immunoglobulin complex, circulating^c back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/GO_0042571

Note that an immunoglobulin complex has the function of antigen binding if a suitable antigen is available.

has super-classes: immunoglobulin complex^c

import across plasma membrane^c back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/GO_0098739

has super-classes: import into cell^c

import into cell^c back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/GO_0098657

has super-classes: transport^c
has sub-classes: import across plasma membrane^c

in vitro design^c back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/OBI_0001285

has super-classes: study design^c

individual human intestinal microsomal fraction^c back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/DIDEO_00000163

Subcellular fractions, derived from endoplasmic reticulum that has been isolated from enterocytes from a single human donor. They contain a rich variety of metaboliz enzymes for assessing first-pass metabolism for orally ingested drugs.

has super-classes: processed material^c

individual human liver microsomal fraction^c back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/DIDEO_00000165

Subcellular fractions, derived from endoplasmic reticulum that has been isolated from liver cells from a single human donor. They contain a rich variety of metaboliz enzymes (e.g. CYP, UGT, FMO) for assessing drug DMPK in vitro, such as metabolic stability, CYP inhibition, CYP phenotyping, metabolite charaterization, etc.

has super-classes: processed material^c

information about decrease of pharmacokinetic area under the curve^c back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/DIDEO_00000051

has super-classes: pharmacokinetic area under curve information^c; i a o 0000136^op min 2 pharmacokinetic area under curve^c

information about increase of pharmacokinetic area under the curve^c back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/DIDEO_00000050

has super-classes: pharmacokinetic area under curve information^c; i a o 0000136^op min 2 pharmacokinetic area under curve^c

information biomacromolecule^c back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/CHEBI_33695

has super-classes: biomacromolecule^c
has sub-classes: polynucleotide^c, protein^c

inhibitor^c back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/CHEBI_35222

has super-classes: biological role^c

inhibitory constant^c back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/DIDEO_00000122

has super-classes: i a o 0000109^c

iron protein^c back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/CHEBI_35136

has super-classes: metalloprotein^c
has sub-classes: hemoprotein^c

itraconazole^c back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/CHEBI_6076

has super-classes: triazole^c

ketoconazole^c back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/CHEBI_48339

has super-classes: imidazoles^c

lactone^c back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/CHEBI_25000

has super-classes: carboxylic ester^c
has sub-classes: delta-lactone^c

lamotrigine glucuronosylation^c back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/DIDEO_00000196

Glucuronidation of lamotrigine; probe substrate of UGT1A4 activity (used to measure UGT1A4 activity)

has super-classes: glucuronosylation^c

LLC-PK subscript(1) cell^c back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/CLO_0007331

has super-classes: cell line cell^c

localization^c back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/GO_0051179

has super-classes: biological_process^c
has sub-classes: establishment of localization^c

lovastatin^c back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/CHEBI_40303

has super-classes: delta-lactone^c

macromolecular complex^c back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/GO_0032991

has super-classes: cellular_component^c
has sub-classes: protein complex^c

macromolecule^c back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/CHEBI_33839

has super-classes: polyatomic entity^c
has sub-classes: biomacromolecule^c

magnesium coordination entity^c back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/CHEBI_33976

has super-classes: alkaline earth coordination entity^c
has sub-classes: magnesium halide^c

magnesium dichloride^c back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/CHEBI_6636

has super-classes: magnesium halide^c

magnesium halide^c back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/CHEBI_51234

has super-classes: magnesium coordination entity^c
has sub-classes: magnesium dichloride^c

main group molecular entity^c back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/CHEBI_33579

has super-classes: molecular entity^c
has sub-classes: p-block molecular entity^c

main-group coordination entity^c back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/CHEBI_36562

has super-classes: coordination entity^c
has sub-classes: alkaline earth coordination entity^c

manufacturer role^c back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/OBI_0000571

has super-classes: b f o 0000023

mass value specification^c back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/OBI_0001929

has super-classes: scalar value specification^c

material anatomical entity^c back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/UBERON_0000465

has super-classes: b f o 0000040
has sub-classes: Portion of body substance^c, anatomical system^c

material component separation^c back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/OBI_0600014

has super-classes: material processing^c
has sub-classes: centrifugation^c

material entity participant in drug-drug interaction^c back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/DIDEO_00000019

A drug entity that participate in a drug-drug interaction but for which its role is not assignable as a precipitant or object.

is equivalent to: (drug product^c or (proper_part_of^op some drug product^c)) and (participates in^op some drug-drug interaction^c)
has super-classes: b f o 0000040

material processing^c back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/OBI_0000094

has super-classes: o b i 0000011^c
has sub-classes: genetic transformation^c, material component separation^c

MDCK cell^c back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/CLO_0007646

has super-classes: cell line cell^c
has sub-classes: MDCK transfected cell^c

MDCK transfected cell^c back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/DIDEO_00000194

Dog cells transfected with human transporter; an in vitro model used to study transporters

is equivalent to: MDCK cell^c and (is_specified_output_of^op some transfection^c)
has super-classes: MDCK cell^c

mechanism of interaction information^c back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/DIDEO_00000022

An instance of this entity would represent the biochemical process by which pharmacokinetic or pharmacodynamic DDI is thought to occur.

has super-classes: i a o 0000030^c; i a o 0000136^op some drug-drug interaction^c

metabolic potential drug-drug interaction^c back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/DIDEO_00000015

is equivalent to: potential drug-drug interaction^c and (i a o 0000136^op some drug metabolic process^c)
has super-classes: potential drug-drug interaction^c
has sub-classes: metabolism induction potential drug-drug interaction^c, metabolism inhibition potential drug-drug interaction^c

metabolic process^c back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/GO_0008152

Note that metabolic processes do not include single functions or processes such as protein-protein interactions, protein-nucleic acids, nor receptor-ligand interactions.

has super-classes: biological_process^c
has sub-classes: cellular metabolic process^c, drug metabolic process^c

metabolism induction potential drug-drug interaction^c back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/DIDEO_00000018

has super-classes: metabolic potential drug-drug interaction^c

metabolism inhibition potential drug-drug interaction^c back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/DIDEO_00000017

has super-classes: metabolic potential drug-drug interaction^c

metabolite^c back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/CHEBI_25212

has super-classes: b f o 0000023

metalloprotein^c back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/CHEBI_35134

has super-classes: protein^c
has sub-classes: iron protein^c

microtiter plate^c back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/OBI_0000192

has super-classes: container^c

Midazolam^c back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/CHEBI_6931

has super-classes: organic heterocyclic compound^c

midazolam 1'-hydroxylation^c back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/DIDEO_00000171

Hydroxylation of midazolam at the 1' position to form 1'-hydroxymidazolam;probe substrate of CYP3A4 activity (used to measure CYP3A4 activity)

has super-classes: hydroxylation^c

mixture^c back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/CHEBI_60004

has super-classes: chemical substance^c
has sub-classes: racemate^c

molecular entity^c back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/CHEBI_23367

has super-classes: chemical entity^c
has sub-classes: main group molecular entity^c, polyatomic entity^c

molecular process^c back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/MOP_0000543

TODO: needs work, formal definition, etc.

has super-classes: b f o 0000015
has sub-classes: breaking of covalent bond^c, formation of covalent bond^c

molecular_function^c back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/GO_0003674

Note that, in addition to forming the root of the molecular function ontology, this term is recommended for use for the annotation of gene products whose molecular function is unknown. Note that when this term is used for annotation, it indicates that no information was available about the molecular function of the gene product annotated as of the date the annotation was made; the evidence code ND, no data, is used to indicate this.

has super-classes: b f o 0000034; bodily process^c
has sub-classes: catalytic activity^c

monocyclic heteroarene^c back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/CHEBI_38179

has super-classes: heteroarene^c
has sub-classes: azole^c

multidrug resistance protein 1^c back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/PR_000001891

has super-classes: protein^c

NAD^c back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/CHEBI_13389

has super-classes: heteroarene^c
has sub-classes: NADH^c

NADH^c back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/CHEBI_16908

has super-classes: NAD^c

NADPH^c back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/CHEBI_16474

has super-classes: heteroarene^c

NADPH--cytochrome P450 reductase^c back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/PR_000013030

Category=gene.

has super-classes: protein^c

narrow therapeutic index^c back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/DIDEO_00000016

has super-classes: b f o 0000016; inheres in^op some drug product^c

negative regulation of biological process^c back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/GO_0048519

has super-classes: regulation of biological process^c

negative regulation of metabolic process^c back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/GO_0009892

is equivalent to: biological regulation^c and (negatively regulates^op some metabolic process^c)
has super-classes: biological regulation^c

negative regulation of transport^c back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/GO_0051051

has super-classes: regulation of transport^c

negative regulation of transporter activity^c back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/GO_0032410

has super-classes: regulation of transporter activity^c

net flux ratio^c back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/DIDEO_00000121

has super-classes: pharmacokinetic parameter ratio^c

nifedipine^c back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/CHEBI_7565

has super-classes: organic heterocyclic compound^c

nifedipine dehydrogenation^c back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/DIDEO_00000173

Dehydrogenation of nifedipine to dehydronifedipine;probe substrate of CYP3A4 activity (used to measure CYP3A4 activity)

has super-classes: dehydrogenation^c

nucleic acid^c back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/CHEBI_33696

has super-classes: polynucleotide^c
has sub-classes: ribonucleic acid^c

nucleic acid reagent^c back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/ERO_0000630

Placeholder for class to be imported from the Reagent Ontology (ReO).

has super-classes: b f o 0000040
has sub-classes: RNA reagent^c

number of doses in a day^c back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/DIDEO_00000184

the frequency of administration of the precipitant during the day

has super-classes: count^c

number of liver donors^c back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/DIDEO_00000190

Number of individual liver samples used

has super-classes: count^c

o b i 0000011^c back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/OBI_0000011

has super-classes: has participant^op some b f o 0000040 and (r o 0000053^op some clinical drug role^c)
has sub-classes: assay^c, drug co-administration^c, group assignment^c, material processing^c, specimen collection process^c, treatment^c

object drug information^c back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/DIDEO_00000011

has super-classes: i a o 0000030^c; (i a o 0000136^op some object drug role^c) and (i a o 0000136^op some drug product^c)

object drug role^c back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/DIDEO_00000012

has super-classes: b f o 0000023

observation design^c back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/OBI_0300311

has super-classes: study design^c

observational data item about drug-drug interaction^c back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/DIDEO_00000003

has super-classes: i a o 0000027^c

obsolete_drug-drug interaction effect^c back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/DIDEO_00000030

has super-classes: obsolete class

obsolete_evidence information content entity^c back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/DIDEO_00000048

has super-classes: obsolete class

omeprazole^c back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/CHEBI_7772

has super-classes: racemate^c

omeprazole 5-hydroxylation^c back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/DIDEO_00000175

Hydroxylation of omeprazole at the 5 position to form 5-hydroxyomeprazole; probe substrate of CYP2C19 activity

is equivalent to: hydroxylation^c and (has input^op some omeprazole^c) and (has output^op some 5'-hydroxyomeprazole^c)
has super-classes: hydroxylation^c

organic cyclic compound^c back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/CHEBI_33832

has super-classes: organic molecule^c
has sub-classes: 4'-hydroxydiclofenac^c, 4-hydroxytolbutamide^c, bupropion^c, diclofenac^c, estradiol^c, organic heterocyclic compound^c

organic heterobicyclic compound^c back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/CHEBI_27171

has super-classes: organic heteropolycyclic compound^c
has sub-classes: benzimidazoles^c, benzothiazepine^c, chlorzoxazone^c

organic heterocyclic compound^c back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/CHEBI_24532

has super-classes: organic cyclic compound^c
has sub-classes: Midazolam^c, heteroarene^c, nifedipine^c, organic heteropolycyclic compound^c

organic heteropolycyclic compound^c back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/CHEBI_38166

has super-classes: organic heterocyclic compound^c
has sub-classes: benzofurans^c, coumarin^c, organic heterobicyclic compound^c, organic heterotetracyclic compound^c, organic heterotricyclic compound^c

organic heterotetracyclic compound^c back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/CHEBI_38163

has super-classes: organic heteropolycyclic compound^c
has sub-classes: dextromethorphan^c

organic heterotricyclic compound^c back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/CHEBI_26979

has super-classes: organic heteropolycyclic compound^c
has sub-classes: phenoxazine^c, triazolobenzodiazepine^c

organic molecular entity^c back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/CHEBI_50860

has super-classes: carbon group molecular entity^c
has sub-classes: 6-hydroxypaclitaxel^c, heteroorganic entity^c, organic molecule^c, paclitaxel^c

organic molecule^c back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/CHEBI_72695

has super-classes: organic molecular entity^c
has sub-classes: organic cyclic compound^c

organism^c back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/OBI_0100026

has super-classes: b f o 0000040
has sub-classes: Dikarya^c, Escherichia coli^c, Homo sapiens^c, Xenopus laevis^c

organochalcogen compound^c back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/CHEBI_36962

has super-classes: heteroorganic entity^c
has sub-classes: organooxygen compound^c

organooxygen compound^c back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/CHEBI_36963

has super-classes: organochalcogen compound^c
has sub-classes: 17alpha-estradiol 3-glucosiduronic acid^c, 6beta-hydroxytestosterone^c, carbon oxoacid^c, ester^c, glutathione^c

overexpression^c back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/INO_0000114

has super-classes: gene expression^c

p-block molecular entity^c back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/CHEBI_33675

has super-classes: main group molecular entity^c
has sub-classes: carbon group molecular entity^c, tolbutamide^c

paclitaxel^c back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/CHEBI_45863

has super-classes: organic molecular entity^c

paclitaxel 6-alpha hydroxylation^c back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/DIDEO_00000177

Hydroxylation of paclitaxel at the 6-alpha position to form 6-alpha-hydroxypaclitaxel; probe substrate of CYP2C8 activity

has super-classes: hydroxylation^c

parallel group design^c back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/OBI_0500006

has super-classes: study design^c

pathological bodily process^c back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/OGMS_0000061

has super-classes: bodily process^c
has sub-classes: adverse event^c

percent^c back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/UO_0000187

has super-classes: ratio^c

percent inhibition^c back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/DIDEO_00000170

Percent inhibition: the percent decrease in activity of a transporter or enzyme in the presence of a compound from activity in the control experiment

has super-classes: i a o 0000109^c

percentage value specification^c back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/DIDEO_00000127

has super-classes: ratio value specification^c

pharmacokinetic area under curve^c back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/DIDEO_00000046

has super-classes: area under curve^c; i a o 0000136^op some part of^op some drug product^c

pharmacokinetic area under curve information^c back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/DIDEO_00000049

is equivalent to: i a o 0000136^op some pharmacokinetic area under curve^c
has super-classes: i a o 0000030^c
has sub-classes: information about decrease of pharmacokinetic area under the curve^c, information about increase of pharmacokinetic area under the curve^c

pharmacokinetic interaction signal^c back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/DIDEO_00000009

Evidence from a kinetic model that a drug-Y has some effect on the absorption, metabolism and elimination of drug-X.

has super-classes: i a o 0000027^c

pharmacokinetic parameter ratio^c back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/DIDEO_00000095

has super-classes: i a o 0000030^c; has value specification^op some value specification^c; i a o 0000136^op some pharmacokinetic process^c
has sub-classes: area under the curve ratio^c, bioavailability ratio^c, drug maximum concentration ratio^c, efflux ratio^c, half-life ratio^c, hepatic clearance ratio^c, net flux ratio^c, renal clearance ratio^c, time to maximum drug concentration ratio^c, volume of distribution ratio^c

pharmacokinetic parameter ratio decrease^c back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/DIDEO_00000097

has super-classes: pharmacokinetic parameter ratio directionality^c

pharmacokinetic parameter ratio directionality^c back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/DIDEO_00000092

has super-classes: i a o 0000030^c; part of^op some pharmacokinetic parameter ratio^c
has sub-classes: pharmacokinetic parameter ratio decrease^c, pharmacokinetic parameter ratio increase^c

pharmacokinetic parameter ratio increase^c back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/DIDEO_00000098

has super-classes: pharmacokinetic parameter ratio directionality^c

pharmacokinetic process^c back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/DIDEO_00000052

has super-classes: biological_process^c

phenacetin O-deethylation^c back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/DIDEO_00000178

O-deethylation of phenacetin to form acetaminophen; probe substrate of CYP1A2 activity

has super-classes: deethylation^c

phenotype characterization^c back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/ERO_0000923

has super-classes: assay^c

phenoxazine^c back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/CHEBI_25970

has super-classes: organic heterotricyclic compound^c
has sub-classes: 7-ethoxyresorufin^c, resorufin^c

physiological observation from clinical study data item^c back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/DIDEO_00000004

is equivalent to: i a o 0000027^c and (i a o 0000136^op some biological_process^c) and (is_specified_output_of^op some b f o 0000055 some r o 0000059 some clinical study design^c)
has super-classes: i a o 0000027^c

polyatomic entity^c back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/CHEBI_36357

has super-classes: molecular entity^c
has sub-classes: heteroatomic molecular entity^c, macromolecule^c

polynucleotide^c back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/CHEBI_15986

has super-classes: information biomacromolecule^c
has sub-classes: nucleic acid^c

pooled human intestinal microsomal fraction^c back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/DIDEO_00000166

Subcellular fractions, derived from endoplasmic reticulum that has been isolated from enterocytes of multiple human donors. They contain a rich variety of metaboliz enzymes for assessing first-pass metabolism for orally ingested drugs.

has super-classes: processed material^c

pooled human liver microsomal fraction^c back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/DIDEO_00000164

Subcellular fractions, derived from endoplasmic reticulum that has been isolated from liver cells from multiple human donors. They contain a rich variety of metaboliz enzymes (e.g. CYP, UGT, FMO) for assessing drug DMPK in vitro, such as metabolic stability, CYP inhibition, CYP phenotyping, metabolite charaterization, etc.

has super-classes: processed material^c

Portion of body substance^c back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/FMA_9669

has super-classes: material anatomical entity^c
has sub-classes: Portion of plasma^c

Portion of plasma^c back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/FMA_62970

has super-classes: Portion of body substance^c

positive regulation of biological process^c back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/GO_0048518

has super-classes: regulation of biological process^c

potential drug-drug interaction^c back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/DIDEO_00000000

has super-classes: i a o 0000030^c; has part^op some drug identifier^c; i a o 0000030^c and (has part^op some data item about biological process^c or observational data item about drug-drug interaction^c or physiological observation from clinical study data item^c or data item from extrapolation^c); (has part^op some object drug information^c) and (has part^op some precipitant drug information^c)
has sub-classes: clinically relevant potential drug-drug interaction^c, metabolic potential drug-drug interaction^c

precipitant drug information^c back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/DIDEO_00000014

has super-classes: i a o 0000030^c; (i a o 0000136^op some precipitant drug role^c) and (i a o 0000136^op some drug product^c)

precipitant drug role^c back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/DIDEO_00000013

has super-classes: b f o 0000023

primary metabolic clearance enzyme role^c back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/DIDEO_00000040

has super-classes: b f o 0000023

primary total clearance enzyme role^c back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/DIDEO_00000039

has super-classes: b f o 0000023; inheres in^op some enzyme^c

probe subtrate role^c back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/DIDEO_00000123

has super-classes: b f o 0000023

processed material^c back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/OBI_0000047

has super-classes: b f o 0000040
has sub-classes: cell pellet^c, cultured cell population^c, device^c, experimentally modified cell in vitro^c, human intestine S9 fraction^c, human intestine cytosolic fraction^c, human liver S9 fraction^c, human liver cytosolic fraction^c, individual human intestinal microsomal fraction^c, individual human liver microsomal fraction^c, pooled human intestinal microsomal fraction^c, pooled human liver microsomal fraction^c

protein^c back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/CHEBI_36080

has super-classes: information biomacromolecule^c
has sub-classes: NADPH--cytochrome P450 reductase^c, metalloprotein^c, multidrug resistance protein 1^c, solute carrier organic anion transporter family member 1B1^c, solute carrier organic anion transporter family member 1B3^c

protein complex^c back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/GO_0043234

A protein complex in this context is meant as a stable set of interacting proteins which can be co-purified by an acceptable method, and where the complex has been shown to exist as an isolated, functional unit in vivo. Acceptable experimental methods include stringent protein purification followed by detection of protein interaction. The following methods should be considered non-acceptable: simple immunoprecipitation, pull-down experiments from cell extracts without further purification, colocalization and 2-hybrid screening. Interactions that should not be captured as protein complexes include: 1) enzyme/substrate, receptor/ligand or any similar transient interactions, unless these are a critical part of the complex assembly or are required e.g. for the receptor to be functional; 2) proteins associated in a pull-down/co-immunoprecipitation assay with no functional link or any evidence that this is a defined biological entity rather than a loose-affinity complex; 3) any complex where the only evidence is based on genetic interaction data; 4) partial complexes, where some subunits (e.g. transmembrane ones) cannot be expressed as recombinant proteins and are excluded from experiments (in this case, independent evidence is necessary to find out the composition of the full complex, if known). Interactions that may be captured as protein complexes include: 1) enzyme/substrate or receptor/ligand if the complex can only assemble and become functional in the presence of both classes of subunits; 2) complexes where one of the members has not been shown to be physically linked to the other(s), but is a homologue of, and has the same functionality as, a protein that has been experimentally demonstrated to form a complex with the other member(s); 3) complexes whose existence is accepted based on localization and pharmacological studies, but for which experimental evidence is not yet available for the complex as a whole.

has super-classes: macromolecular complex^c
has sub-classes: immunoglobulin complex^c

protocol^c back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/OBI_0000272

has super-classes: i a o 0000033^c
has sub-classes: adverse drug reaction causality evaluation protocol^c

public adverse event reporting database^c back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/DIDEO_00000082

has super-classes: i a o 0000100^c

racemate^c back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/CHEBI_60911

has super-classes: mixture^c
has sub-classes: fluvastatin^c, omeprazole^c

ratio^c back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/UO_0000190

has super-classes: dimensionless unit^c
has sub-classes: fold^c, percent^c

ratio value specification^c back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/DIDEO_00000126

has super-classes: value specification^c
has sub-classes: percentage value specification^c

recombinant protein production host role^c back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/DIDEO_00000183

An in vitro system that uses a combination of genetic pieces typically in a plasmid that is incorporated into a host cell which is used to produce the protein of interest

has super-classes: target of material addition role^c

regulation of biological process^c back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/GO_0050789

has super-classes: biological regulation^c
has sub-classes: negative regulation of biological process^c, positive regulation of biological process^c, regulation of localization^c

regulation of localization^c back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/GO_0032879

has super-classes: regulation of biological process^c
has sub-classes: regulation of transport^c

regulation of transport^c back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/GO_0051049

has super-classes: regulation of localization^c
has sub-classes: negative regulation of transport^c, regulation of transporter activity^c

regulation of transporter activity^c back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/GO_0032409

has super-classes: regulation of transport^c
has sub-classes: negative regulation of transporter activity^c

renal clearance ratio^c back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/DIDEO_00000094

has super-classes: pharmacokinetic parameter ratio^c

reported drug-drug interaction^c back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/DIDEO_00000008

An instance of a drug-drug interaction that has been identified in case report or study.

has super-classes: drug-drug interaction^c; drug-drug interaction^c and (inverse i a o 0000136^op some i a o 0000311^c)

resorufin^c back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/CHEBI_51602

has super-classes: phenoxazine^c

ribonucleic acid^c back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/CHEBI_33697

has super-classes: nucleic acid^c

RNA interference oligonucleotide^c back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/ERO_0001206

Placeholder for class to be imported from the Reagent Ontology (ReO).

has super-classes: RNA oligonucleotide^c
has sub-classes: siRNA oligonucleotide^c

RNA oligonucleotide^c back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/ERO_0001205

Placeholder for class to be imported from the Reagent Ontology (ReO).

has super-classes: RNA reagent^c
has sub-classes: RNA interference oligonucleotide^c

RNA reagent^c back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/ERO_0001202

Placeholder for class to be imported from the Reagent Ontology (ReO).

has super-classes: nucleic acid reagent^c
has sub-classes: RNA oligonucleotide^c

role of scattered molecular aggregate^c back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/DRON_00000030

is equivalent to: b f o 0000023 and (inheres in^op some scattered molecular aggregate^c)
has super-classes: b f o 0000023
has sub-classes: active ingredient^c

rosuvastatin^c back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/CHEBI_38545

has super-classes: dihydroxy monocarboxylic acid^c

sandwich cultured hepatocyte population^c back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/DIDEO_00000154

has super-classes: cultured cell population^c

scalar value specification^c back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/OBI_0001931

has super-classes: value specification^c
has sub-classes: mass value specification^c

scattered molecular aggregate^c back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/OBI_0000576

has super-classes: b f o 0000027^c

severe adverse event^c back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/OAE_0000631

has super-classes: adverse event^c

simvastatin^c back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/CHEBI_9150

has super-classes: delta-lactone^c

siRNA knockout Caco-2 cell^c back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/DIDEO_00000188

Caco-2 cells treated with siRNA designed to down-regulate specific enzymes or transporters

is equivalent to: Caco-2 cell^c and (is_specified_output_of^op some gene knock out^c and (o b i 0000293^op some siRNA oligonucleotide^c))
has super-classes: Caco-2 cell^c

siRNA oligonucleotide^c back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/ERO_0001209

Placeholder for class to be imported from the Reagent Ontology (ReO).

has super-classes: RNA interference oligonucleotide^c

solute carrier organic anion transporter family member 1B1^c back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/PR_000015223

Category=gene.

has super-classes: protein^c

solute carrier organic anion transporter family member 1B3^c back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/PR_000015224

Category=gene.

has super-classes: protein^c

specimen^c back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/OBI_0100051

has super-classes: b f o 0000040
has sub-classes: tissue specimen^c

specimen collection process^c back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/OBI_0000659

has super-classes: o b i 0000011^c

study design^c back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/OBI_0500000

has super-classes: i a o 0000104^c
has sub-classes: clinical study design^c, ex vivo design^c, in vitro design^c, observation design^c, parallel group design^c

supernatant role^c back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/OBI_0000034

has super-classes: b f o 0000023

target of material addition role^c back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/OBI_0000444

has super-classes: b f o 0000023
has sub-classes: recombinant protein production host role^c

testosterone 6-beta-hydroxylation^c back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/DIDEO_00000180

Hydroxylation of testosterone at the 6-beta position to form 6-beta-hydroxytestosterone; probe substrate of CYP3A4 activity

has super-classes: hydroxylation^c

time to maximum drug concentration ratio^c back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/DIDEO_00000119

has super-classes: pharmacokinetic parameter ratio^c

tissue specimen^c back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/OBI_0001479

has super-classes: specimen^c

tolbutamide^c back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/CHEBI_27999

has super-classes: p-block molecular entity^c

tolbutamide methylhydroxylation^c back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/DIDEO_00000192

Methyhydroxylation of tolbutamide to form hydroxytolbutamide;probe substrate of CYP2D6 activity

has super-classes: hydroxylation^c

transfection^c back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/OBI_0001152

has super-classes: genetic transformation^c

transgenic animal hepatocyte population^c back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/DIDEO_00000153

Cells isolated from livers of transgenic animals; an in vitro model system for human metabolism or transport

has super-classes: cultured cell population^c

transport^c back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/GO_0006810

has super-classes: establishment of localization^c
has sub-classes: import into cell^c

treatment^c back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/OGMS_0000090

has super-classes: o b i 0000011^c
has sub-classes: drug administration^c

triazolam^c back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/CHEBI_9674

has super-classes: triazolobenzodiazepine^c

triazole^c back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/CHEBI_38597

has super-classes: azole^c
has sub-classes: fluconazole^c, itraconazole^c

triazolobenzodiazepine^c back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/CHEBI_35501

has super-classes: organic heterotricyclic compound^c
has sub-classes: triazolam^c

U.S. Food and Drug Administration drug label^c back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/DIDEO_00000045

has super-classes: drug package insert^c

UDP-alpha-D-glucuronic acid^c back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/CHEBI_17200

has super-classes: heteroarene^c

unit^c back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/UO_0000000

has super-classes: i a o 0000030^c
has sub-classes: dimensionless unit^c

value specification^c back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/OBI_0001933

has super-classes: i a o 0000030^c
has sub-classes: ratio value specification^c, scalar value specification^c
is in domain of: has specified value^dp

volume of distribution ratio^c back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/DIDEO_00000118

has super-classes: pharmacokinetic parameter ratio^c

Xenopus laevis^c back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/NCBITaxon_8355

has super-classes: organism^c

This HTML document was obtained by processing the OWL ontology source code through LODE, Live OWL Documentation Environment, developed by Silvio Peroni.

DIDEO

Abstract

Table of Content

Classes

1-benzofuransc back to ToC or Class ToC

17alpha-estradiol 3-glucosiduronic acidc back to ToC or Class ToC

293 transfected cellc back to ToC or Class ToC

293-derived cellc back to ToC or Class ToC

3'-phospho-5'-adenylyl sulfatec back to ToC or Class ToC

4'-hydroxydiclofenacc back to ToC or Class ToC

4-hydroxytolbutamidec back to ToC or Class ToC

5'-hydroxyomeprazolec back to ToC or Class ToC

5-[2-(dimethylamino)ethyl]-2-(4-methoxyphenyl)-4-oxo-2,3,4,5-tetrahydro-1,5-benzothiazepin-3-yl acetatec back to ToC or Class ToC

6-hydroxypaclitaxelc back to ToC or Class ToC

6beta-hydroxytestosteronec back to ToC or Class ToC

7-ethoxyresorufinc back to ToC or Class ToC

7-ethoxyresorufin O-deethylationc back to ToC or Class ToC

absorbabilityc back to ToC or Class ToC

absorbability measurement datumc back to ToC or Class ToC

absorption of materialc back to ToC or Class ToC

active ingredientc back to ToC or Class ToC

active ingredient quantification specificationc back to ToC or Class ToC

adverse drug eventc back to ToC or Class ToC

adverse drug reaction causality evaluation protocolc back to ToC or Class ToC

adverse eventc back to ToC or Class ToC

alkaline earth coordination entityc back to ToC or Class ToC

amiodaronec back to ToC or Class ToC

anatomical systemc back to ToC or Class ToC

area under curvec back to ToC or Class ToC

area under the curve ratioc back to ToC or Class ToC

assayc back to ToC or Class ToC

atorvastatinc back to ToC or Class ToC

azolec back to ToC or Class ToC

baculovirus-insect recombinant protein production host cellc back to ToC or Class ToC

benzimidazolesc back to ToC or Class ToC

benzofuransc back to ToC or Class ToC

benzothiazepinec back to ToC or Class ToC

bioavailabilityc back to ToC or Class ToC

bioavailability measurement datumc back to ToC or Class ToC

bioavailability ratioc back to ToC or Class ToC

biological regulationc back to ToC or Class ToC

biological rolec back to ToC or Class ToC

biological_processc back to ToC or Class ToC

biomacromoleculec back to ToC or Class ToC

bodily processc back to ToC or Class ToC

breaking of covalent bondc back to ToC or Class ToC

Bufuralolc back to ToC or Class ToC

bufuralol 1'-hydroxylationc back to ToC or Class ToC

bupropionc back to ToC or Class ToC

bupropion hydroxylationc back to ToC or Class ToC

Caco-2 cellc back to ToC or Class ToC

carbon group molecular entityc back to ToC or Class ToC

carbon oxoacidc back to ToC or Class ToC

carboxylic acidc back to ToC or Class ToC

carboxylic esterc back to ToC or Class ToC

catalytic activityc back to ToC or Class ToC

causal adverse drug eventc back to ToC or Class ToC

cell linec back to ToC or Class ToC

cell line cellc back to ToC or Class ToC

cell pelletc back to ToC or Class ToC

cellular metabolic processc back to ToC or Class ToC

cellular processc back to ToC or Class ToC

cellular_componentc back to ToC or Class ToC

centrifugationc back to ToC or Class ToC

centrifuge pellet rolec back to ToC or Class ToC

chemical entityc back to ToC or Class ToC

chemical substancec back to ToC or Class ToC

chlorzoxazonec back to ToC or Class ToC

chlorzoxazone 6-hydroxylationc back to ToC or Class ToC

CHO cellc back to ToC or Class ToC

CHO transfected cellc back to ToC or Class ToC

clearance measurement datumc back to ToC or Class ToC

clinical drug rolec back to ToC or Class ToC

clinical studyc back to ToC or Class ToC

clinical study designc back to ToC or Class ToC

clinically relevant potential drug-drug interactionc back to ToC or Class ToC

containerc back to ToC or Class ToC

contraindicationc back to ToC or Class ToC

coordination entityc back to ToC or Class ToC

coumarinc back to ToC or Class ToC

1-benzofurans^c back to ToC or Class ToC

17alpha-estradiol 3-glucosiduronic acid^c back to ToC or Class ToC

293 transfected cell^c back to ToC or Class ToC

293-derived cell^c back to ToC or Class ToC

3'-phospho-5'-adenylyl sulfate^c back to ToC or Class ToC

4'-hydroxydiclofenac^c back to ToC or Class ToC

4-hydroxytolbutamide^c back to ToC or Class ToC

5'-hydroxyomeprazole^c back to ToC or Class ToC

5-[2-(dimethylamino)ethyl]-2-(4-methoxyphenyl)-4-oxo-2,3,4,5-tetrahydro-1,5-benzothiazepin-3-yl acetate^c back to ToC or Class ToC

6-hydroxypaclitaxel^c back to ToC or Class ToC

6beta-hydroxytestosterone^c back to ToC or Class ToC

7-ethoxyresorufin^c back to ToC or Class ToC

7-ethoxyresorufin O-deethylation^c back to ToC or Class ToC

absorbability^c back to ToC or Class ToC

absorbability measurement datum^c back to ToC or Class ToC

absorption of material^c back to ToC or Class ToC

active ingredient^c back to ToC or Class ToC

active ingredient quantification specification^c back to ToC or Class ToC

adverse drug event^c back to ToC or Class ToC

adverse drug reaction causality evaluation protocol^c back to ToC or Class ToC

adverse event^c back to ToC or Class ToC

alkaline earth coordination entity^c back to ToC or Class ToC

amiodarone^c back to ToC or Class ToC

anatomical system^c back to ToC or Class ToC

area under curve^c back to ToC or Class ToC

area under the curve ratio^c back to ToC or Class ToC

assay^c back to ToC or Class ToC

atorvastatin^c back to ToC or Class ToC

azole^c back to ToC or Class ToC

baculovirus-insect recombinant protein production host cell^c back to ToC or Class ToC

benzimidazoles^c back to ToC or Class ToC

benzofurans^c back to ToC or Class ToC

benzothiazepine^c back to ToC or Class ToC

bioavailability^c back to ToC or Class ToC

bioavailability measurement datum^c back to ToC or Class ToC

bioavailability ratio^c back to ToC or Class ToC

biological regulation^c back to ToC or Class ToC

biological role^c back to ToC or Class ToC

biological_process^c back to ToC or Class ToC

biomacromolecule^c back to ToC or Class ToC

bodily process^c back to ToC or Class ToC

breaking of covalent bond^c back to ToC or Class ToC

Bufuralol^c back to ToC or Class ToC

bufuralol 1'-hydroxylation^c back to ToC or Class ToC

bupropion^c back to ToC or Class ToC

bupropion hydroxylation^c back to ToC or Class ToC

Caco-2 cell^c back to ToC or Class ToC

carbon group molecular entity^c back to ToC or Class ToC

carbon oxoacid^c back to ToC or Class ToC

carboxylic acid^c back to ToC or Class ToC

carboxylic ester^c back to ToC or Class ToC

catalytic activity^c back to ToC or Class ToC

causal adverse drug event^c back to ToC or Class ToC

cell line^c back to ToC or Class ToC

cell line cell^c back to ToC or Class ToC

cell pellet^c back to ToC or Class ToC

cellular metabolic process^c back to ToC or Class ToC

cellular process^c back to ToC or Class ToC

cellular_component^c back to ToC or Class ToC

centrifugation^c back to ToC or Class ToC

centrifuge pellet role^c back to ToC or Class ToC

chemical entity^c back to ToC or Class ToC

chemical substance^c back to ToC or Class ToC

chlorzoxazone^c back to ToC or Class ToC

chlorzoxazone 6-hydroxylation^c back to ToC or Class ToC

CHO cell^c back to ToC or Class ToC

CHO transfected cell^c back to ToC or Class ToC

clearance measurement datum^c back to ToC or Class ToC

clinical drug role^c back to ToC or Class ToC

clinical study^c back to ToC or Class ToC

clinical study design^c back to ToC or Class ToC

clinically relevant potential drug-drug interaction^c back to ToC or Class ToC

container^c back to ToC or Class ToC

contraindication^c back to ToC or Class ToC

coordination entity^c back to ToC or Class ToC

coumarin^c back to ToC or Class ToC

coumarin 7-hydroxylation^c back to ToC or Class ToC

count^c back to ToC or Class ToC

cryopreserved human hepatocyte population^c back to ToC or Class ToC

cultured cell^c back to ToC or Class ToC